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Local treatment for cervical intra-epithelial neoplasia (CIN) involves the removal of 
the affected part of the tissue and is >95% effective in preventing re-invasive disease. 
However, removal of part of the cervix is linked to significant adverse sequelae, 
including preterm birth; with cone depth and radicality of treatment correlating to the 
frequency and severity of adverse events. Since pre-treatment cervix length vary 
amongst women, the percentage of cervix excised may correlate more accurately to 
risk than absolute dimensions. Attenuated total reflectance, Fourier-transform infra-
red (ATR-FTIR) spectroscopy detected that treatment for CIN significantly alters the 
biochemical fingerprint in the cervix, compared with women who have not had 
treatment; this is due to the excision of cervical tissue rather than a disease controlling 
effect. However, the spectra did not correlate to the cone depth or proportion of 
cervical length excised. Post-hoc analyses of patient characteristics found that spectral 
absorbance was different for treated women according to whether they were 
current/non-smokers; nulliparous/parous; by luteal/follicular phase; and by combined 
oral contraceptive pill use; these patient characteristics are likely to have affected the 
excisional outcomes. As traditional IR techniques are limited by the effect of 
diffraction of ~3 µm to 30 µm, we assessed the potential of scanning near-field optical 
microscopy in combination with an IR free electron laser (SNOM-IR-FEL), in 
determining the biophysical properties of abnormal cervical cells. SNOM-IR-FEL is 
able to distinguish between normal and various grades of cervical abnormalities at 
designated wavelengths associated with DNA, amides I and II and lipids, at spatial 




1.1 The global burden of cervical cancer 
In 2012, around 528,000 new cases of cervical cancer were diagnosed, ranking it the 
fourth most common cancer in women globally after breast, colorectal, and lung 
cancers, and the second most common cancer in developing countries (World Health 
Organization [WHO], 2015; Ferlay et al., 2013a). In Europe, cervical cancer is the 
sixth most common cancer in females with approximately 58,300 new cases in 2012 
and around 24,400 deaths, with Romania having the highest World age-standardised 
rates of incidence and Switzerland the lowest (Cancer Research UK, 2015). Whilst 
immunisation and screening programs have reduced morbidity and mortality in 
developed regions, the global mortality rate remains high at 52%, with 85% of the 
270, 000 deaths each year occurring in developing countries (WHO, 2015).  
The incidence of cervical cancer varies widely by country. High risk regions 
(affecting more than 30 women in every 100, 000 women) include Eastern Africa 
(43%), Melanesia (33%), Southern and Middle Africa (32% and 31%, respectively); 
low risk regions include Australia and New Zealand (6%) and Western Asia (4%); 
(Ferlay et al., 2013a). Almost one fifth of all new cases are diagnosed in India (WHO, 
2013). The increased incidence and high mortality in high risk regions is due to the 
absence of widely available, good quality screening services (Vaccarella et al., 2013). 
With little or no access to care, the death rate was estimated in 2008 to contribute to 
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more than 10% of the economic loss in the developing world (American Cancer 
Society and LIVESTRONG, 2010).  
Cervical cancer is a preventable and treatable disease with an estimated 1.55 million 
women still alive 5 years after diagnosis in 2008 (Anolue et al., 2014; Ferlay et al., 
2008). The Worldwide healthcare costs per year have been valued at 3.2 billion USD, 
with medication costs estimated at 865.4 million USD, and nonmedical costs at 703.6 
million USD (Muka et al., 2015). Absenteeism and the inability to work result in a 
global productivity loss estimated at 1.7 million USD per year. By 2030, cervical 
cancer is expected to kill more than 474, 000 women per year (American Cancer 
Society, 2013), significantly increasing the global economic burden.   
1.2 UK burden of cervical cancer 
1.2.1 Incidence 
In the UK, around 9 new cases per 100,000 females were diagnosed in 2012 (Table 1); 
(Cancer Research UK, 2015).  
 England Wales Scotland 
Northern  
Ireland UK 
Cases 2482 174 295 93 3044 
Crude Rate 9.1 11.1 10.8 10.0 9.4 
AS Rate 9.3 11.5 10.9 10.2 9.5 
AS Rate - 95% 
LCL 8.9 9.8 9.6 8.1 9.2 
AS Rate - 95% 
UCL 9.6 13.2 12.1 12.2 9.9 
95% LCL and 95% UCL are the 95% lower and upper confidence limits around the AS Rate. AS: Age-
Standardised; LCL: Lower confidence limit; UCL: Upper confidence limit.  
Table 1. Number of new cases, crude and European age-standardised (AS) incidence rates per 
100,000 population, females, UK (reproduced from Cancer Research UK: Incidence, 2015). 
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Cervical cancer is the twelfth most common cancer in the UK with the age-
standardised rates being highest in Wales (Cancer Research UK, 2015). The incidence 
of cervical cancer varies widely by geographical region, with rates being lowest in 
South and East of England, and the highest rates being found in parts of Scotland, 
Northern Ireland and the North of England (Trent Cancer Registry; 2012; National 
Cancer Intelligence Network [NCIN], 2008). The differences may be linked to 
differences in sexual attitudes, an increased prevalence in smoking and higher parity 
at a younger age.  
The incidence of cervical cancer is strongly associated with two, age-specific peaks: 
19 new cases per 100,000 in women aged 25-29 years, and 12 new cases per 100,000 
in women aged 85-89 years (Cancer Research UK, 2015). The first peak is thought to 
be due to women becoming sexually active and subsequently infected with human 
Papillomavirus (HPV), an established risk factor for cervical cancer (Foley et al., 
2011). Between 2010 and 2012 in the UK, 78% of cervical cancers were diagnosed in 
25-64 year olds, with 11% of new cases diagnosed in women aged 75 years and over 
(Cancer Research UK, 2015).  
The reasons for the second peak in older women are not fully understood and may be 
a combination of factors, including a lack of knowledge of what causes cervical 
cancer and who can be affected, or late cytological changes that were not present 
earlier in life and not detected by earlier screening. Additionally, there is the 
perception that this cancer is a younger woman’s disease which promotes a drop off in 
attendance for screening in women aged 60+ years (Sherman et al., 2015). Other 
factors may include an immune system compromised by advancing age and where a 
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latent HPV infection suddenly becomes active, or the onset of other comorbidities and 
the use of associated medications needed to treat and control them.  
Over the last decade, the incidence of cervical cancer has decreased significantly 
overall due to the deployment of the UK’s national cervical screening programme in 
1988, with the lifetime risk of a new-born child developing cervical cancer at some 
point in their life being 1 in 139 (2010 estimate); (Cancer Research UK, 2015). 
However, although the incidence rates for women aged 25-34 initially decreased by 
35% between 1985 and 1987, and again between 2002 and 2004, increased rates of 
HPV infection and smoking prevalence in this age group has seen incidence rates rise 
by 52% (Trent Cancer Registry, 2012; Foley et al., 2011).    
Almost 76% of cervical cancers are reported as squamous cell carcinomas (SCC),  
10-15% are reported as adenocarcinoma (glandular lesions) and adenosquamous cell 
carcinomas (mixed glandular and squamous lesions), with the remaining cases being 
typed as poorly specified (Vizcaino et al., 1998). There is mounting evidence that the 
incidence of SCC is falling worldwide, whilst the incidence of adenocarcinoma is 
increasing, as is the risk of adenocarcinoma per population (Smith et al., 2000; 
Vizcaino et al., 2000; Vizcaino et al., 1998). These results suggest current cytology 
screening practices that were originally developed to identify squamous lesions are 
inadequate in the detection of adenocarcinomas.   
There is some evidence that the incidence of cervical cancer in England is associated 
with ethnicity, with age-standardised incidence rates for White and Black women 
ranging from 8.2 to 8.7 per 100,000 and 6.3 to 11.2 per 100,000, respectively; whilst 
the rates of cervical cancer in Asian women are significantly lower, ranging from 3.6 
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to 6.5 per 100,000 (NCIN and Cancer Research UK, 2009). These differences are 
likely to be caused by different cultural attitudes towards sex. 
1.2.2 Mortality 
In the UK, there were 3 deaths per 100,000 females due to cervical cancer in 2012, 
ranking it the 17th most common cancer death among females, with age-standardised 
mortality rates being highest in Scotland (Table 2); (Cancer Research UK, 2014a). 
  England Wales Scotland 
Northern 
Ireland UK 
Deaths 742 43 112 22 919 
Crude Rate 2.7 2.7 4.1 2.4 2.8 
AS Rate 2.1 2.1 3.2 2.2 2.2 
AS Rate - 95% LCL 2 1.4 2.6 1.3 2.1 
AS Rate - 95% UCL 2.3 2.7 3.8 3.1 2.4 
95% LCL and 95% UCL are the 95% lower and upper confidence limits around the AS Rate. AS:  
Age-Standardised; LCL: Lower confidence limit; UCL: Upper confidence limit. 
Table 2. Number of deaths, crude and European age-standardised (AS) mortality rates per 
100,000 population, females, UK (reproduced from Cancer Research UK [Mortality], 2014a).  
Mortality rates follow a similar pattern as for incidence and vary by health region. 
Rates are highest in the North of England and lowest in the South of England (NCIN, 
2005). During the period 2010-2012, more than 52% of deaths from cervical cancer 
occurred in women aged 25-64 years, and approximately 30% of deaths occurred in 
women aged 75 years and over (Cancer Research UK, 2014a). Mortality rates overall 
have decreased significantly following improvements to the national screening 
programme in the 1980’s which is estimated to prevent approximately 5,000 deaths 
each year (Peto et al., 2004). Survival rates at 1 and 5 years after diagnosis are 83% 
and 67%, respectively (Bate and Baker, 2015). 
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The significant increase in mortality rates for Scottish women is thought to be due to 
the continuing decline in the number of women participating in the cervical screening 
programme in Scotland, with 70.4% of women aged between 20-60 years attending in 
2014/15, continuing a 10-year fall in uptake since 2005/06, which had 78% 
participation (Information Services Division, Scotland, 2015). These figures suggest 
around 30% of Scottish women are at risk of developing cervical cancer. 
1.2.3 Economic costs 
The NHS spends around £21 million treating cervical cancer per year (2011), 
government loses over £9 million in tax revenue as a result of absenteeism and the 
inability to work, and the combined financial costs to women is approximately £14 
million, with a significant portion of these costs and losses associated with treating 
more advanced cervical cancers (Salter, 2014). Although the percentage of women 
aged 25-64 years in 2013/14 in England who had an adequate cervical screening test 
in the last 5 years was 77.8%, this was significantly lower (63.3%) for those aged 
between 25-29 years who are screened every 3 years (Screening and Immunisations 
team, Health & Social Care Information Centre, 2014), thus leaving a significant 
number of women with an increased risk of developing more serious cervical cancers.  
The reasons behind falling screen rates are varied, often contentious, and include 
difficulty in being able to fit screening attendance around work and family 
commitments; embarrassment; experience of discomfort during the collection of 
cervical cells; poor awareness of what screening is for; and extending services to hard-
to-reach groups such as immigrant and older women. Achieving a 100% screening 
uptake would reduce the incidence of more invasive cervical cancers, NHS costs 
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would fall by almost 50%, tax loses would fall to about a third, and total costs to 
women would fall by approximately 40% (Salter, 2014). Conversely, if national 
screening rates continue to fall to 70%, it is estimated that costs to the NHS alone 
would increase by another £6.5 million per year.   
1.3 Structure and function of the cervix 
The cervix is the tube-shaped opening to the uterus that protrudes into the vagina and 
plays a vital role in the overall reproductive health of women. The key functions of the 
cervix include permitting the passage of menstrual fluid, promoting fertility, and 
protecting the uterus, upper reproductive tract and a developing foetus from pathogens 
(Reproductive Health Technologies Project, 2000). The cervix is approximately 3-4 
cm long and 2.5 cm wide, although the size and shape of the cervix differs among 
women according to age, hormonal status, parity, pregnancy, and surgical treatment 
(Martyn et al., 2014; Mazouni et al., 2005; Pardo et al., 2003). The cervix is 
composed of two parts: the ectocervix is composed squamous epithelium, and the 
endocervix is composed of glandular (columnar) or mucin-secreting epithelium that 




Bliss (Illustrator; source: National Cancer Institute), 2004 
Figure 1. Glandular cells of the endocervix and squamous cells of the ectocervix. 
1.3.1 Squamous epithelium  
The ectocervix is covered by 15-20 layers of glycogen-rich, stratified, non-
keratinizing cells which are opaque and pale pink in colour (International Agency for 
Research on Cancer [IRAC], 2016a). Native epithelium defines tissue that developed 
during embryonic life. Newly formed metaplastic tissue develops as a result of 
physiological influences, such as those experienced at puberty and during the early 
reproductive years. Age and menopausal status also affects the development of 
metaplastic epithelium. The histological makeup of squamous epithelium is composed 
of 4 cellular layers including the basal and parabasal cell layers, and the intermediate 
and superficial cell layers. The basal cells are attached to the basement membrane, and 
feature large nuclei suspended in very little cytoplasm. The membrane separates these 




Figure 2. The differing layers of stratified squamous epithelium (x 20). 
The basal cells divide, mature and are pushed upwards to form the parabasal layer 
(IRAC, 2016a). As this layer undergoes further maturation to form the intermediate 
layer, the cells become polygonal in shape and their nuclei smaller. Finally, these cells 
mature into flattened cells, with an abundance of cytoplasm containing pyknotic 
nuclei, where the chromatin has undergone irreversible condensation as it prepares for 
programmed cell death (apoptosis); (Figure 3).  
 
Halliwell, 2016a 
Figure 3. Unstained normal squamous epithelial cells of the superficial layer of the ectocervix.  
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The cells of the intermediate and superficial layers have plentiful glycogen, indicative 
of normal maturation and development. Abnormal development is associated with an 
absence of glycogen production (IRAC, 2016a). Proper maturation of the squamous 
epithelium is controlled oestrogen. Following menopause, the cells do not mature 
beyond the parabasal layer or undergo glycogenation.   
1.3.2 Glandular epithelium  
The endocervical canal, which lies just inside the cervix, is composed of a single layer 
of glandular cells (IRAC, 2016a). The underlying blood vessels of the stroma are 
visible through the single layer, making the cells reddish in appearance. These tall 
‘columnar’ cells are long, packed with cytoplasm, with their nuclei occupying the end 
of the cell that is attached to the basement membrane (Figure 4).  
 
(IRAC, 2016c) 
Figure 4. Glandular (columnar) cells of the endocervix canal (x 40).  
Glandular epithelium unites with the endometrial epithelium at its upper margin, and 
fuses with the squamous epithelium at its lower margin, called the squamo-columnar 
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junction.  This junction may appear at different sites within the endocervix as it varies 
according to age, menstrual and pregnancy status, and oral contraceptive use 
(Eurocytology, 2015). Mitosis and glycogen production do not occur in glandular 
cells.  
1.3.3 The transformation zone 
Anaerobic conversion of vaginal glycogen to mainly acetic and lactic acids by micro-
organisms, especially the Lactobacillus spp., maintains normal vaginal pH to between 
3.8 and 4.5 (Boskey et al., 1999). During puberty and at first pregnancy, the influence 
of oestrogen triggers the cervix to increase in volume, causing the endocervix to evert 
onto the ectocervix (portio vaginalis), exposing the delicate glandular cells to the more 
acidic environment (Eurocytology, 2015). The epithelium begins to undergo dynamic 
changes (metaplasia); this is called the ‘transformation zone’ (Figure 5).   
Within the transformation zone, the glandular cells are gradually replaced by the more 
durable squamous epithelial cells (Sun et al., 1992). The transformation zone is the 
common site of cervical neoplasia (Burghardt, 1986), whilst only 3% of cervical 






Cancer Research UK, 2014b 
Figure 5. The transformation zone of the cervix located at the ectocervix and endocervix. 
Vaginal acidity destroys the glandular epithelium, which is replaced by newly formed 
squamous epithelium (squamous metaplasia). The process prompts the formation of 
undifferentiated, sub-glandular reserve cells, from which the metaplastic squamous 
epithelium is eventually derived (IRAC, 2016a). Initially, there is no stratification of 
this immature metaplastic squamous epithelium and they are absent of glycogen. 
Following differentiation and stratification, the mature cells appear very similar to the 
original squamous epithelium. The replacement of glandular epithelium by 
metaplastic squamous epithelium is irreversible.  
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In most women, the immature metaplastic epithelium develops into mature squamous 
metaplastic epithelium and is functionally similar to the original squamous epithelium, 
including glycogen production (IRAC, 2016a). However, cervical intraepithelial 
neoplasia (CIN) arises following persistent infection with oncogenic types of HPV, 
which infect the immature basal squamous metaplastic cells, transforming them into 
cells with aberrant cellular functions (Bosch et al., 1995). These cells proliferate to 
form an abnormal epithelium, termed ‘dyskaryosis’ which can spontaneously regress 
to normal, remain static or progress into more invasive lesions (IRAC, 2016a). The 
high turnover rate and low maturation of cells in the transformation zone makes it 
especially vulnerable to pre-cancerous changes (Reproductive Health Technologies 
Project, 2000).  
Both glandular and squamous epithelial cells are collected during cervical screening to 
detect the presence of these atypical cells within the transformation zone. 
1.4 Causes of cervical cancer 
HPV is a group of very common viruses that includes over 100 different types (WHO, 
2015), with approximately 35 types involved in the infection of the genital tract 




Adobe Systems, 2015 (purchased under licence) 
Figure 6. HPV types and associated diseases.
Cervical cancer is mainly caused through a sexually transmitted infection with HPV, 
with 84.1% of invasive cervical cancers associated with infection with high-risk types 
16 and 18 (Ramakrishnan et al., 2015). Research has shown that HPV 16 is associated 
with SCC, and HPV 18 is more commonly associated with adenocarcinoma (Clifford 
et al., 2003). Genital HPV infection in women is largely acquired in adolescence, 
shortly after commencing sexual activity, although worldwide prevalence varies 
according to geography and is influenced by cultural attitudes to sexual behaviour 
(Smith et al., 2008).  Whilst many HPV infections are transient and clear up without 
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intervention within 1 to 2 years, for some women the infection persists and CIN can 
develop in as little as 2-4 years (Kyrgiou and Shafi, 2014).  
The environmental risk factors for HPV persistence and the development of high-
grade lesions and cervical cancer include high parity, long-term oral contraceptive 
use, and co-infection with other sexually transmitted agents, including chlamydia, 
Herpes simplex virus 2 (HSV-2) and Human immunodeficiency virus (HIV); 
(Castellsagué et al., 2002). Current smoking is associated with a significantly 
increased risk of SCC but not for adenocarcinoma (Berrington de González et al., 
2004). Pure adenocarcinoma has a higher rate of incidence in younger patients 
(Sasieni and Adams, 2001), and is linked with a poorer survival outcome than SCC 
(Liu et al., 2001). Other non-environmental risk factors include the behaviour of the 
host’s immune system, HPV genotypes, and extent of integration into the host’s DNA 
(Castellsagué et al., 2002). Co-infections with taxonomically similar HPV types have 
been found to reduce the likelihood of progression to high-grade lesions in HIV 
positive women, possibly as a result of an immune cross-protection (Sobota et al., 
2014). Research investigating a link between cervical HPV persistence and nutrition 
revealed that a diet rich in fruits, vegetables, Vitamins C and E, beta- and alpha-
carotene, lycopene, and lutein and crytoxanthin (a natural carotenoid pigment), 
showed a ‘possible’ protective effect (García-Closas et al., 2005). Antioxidants may 
play a protective role by influencing the duration of HPV infection, since plasma 
concentrations of some carotenoids such as lutein and Vitamin E, were found to be 
inversely associated with HPV persistence (Castle and Giuliano, 2003). 
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1.5 The HPV genome   
HPV consists of ~8000 base-pair circular DNA molecules packaged inside a protein 
coat Muñoz et al., 2006). The virus is approximately 55 nm in size, with seven 
important coding regions split into three functional coding groups (Faridi et al., 2011); 
(Figure 7). 
           
URR: Upstream regulatory region.                                                              (Microsoft, 2016). 
Figure 7. Structure of HPV. 
The ‘early’ coding genes comprise the first functional group (E group), a long 
upstream regulatory region (URR) or long control region (LCR) comprises the second 
functional group, and separates the ‘early’ genes from the ‘late’ coding genes  
(L group); (Faridi et al., 2011; Muñoz et al., 2006).  
The ‘early’ genes include E1/E2 which code for proteins that control the functionality 
of oncogenic genes E6 and E7; E4 may code for a protein that governs virus release 
from the cell; E5 codes for a protein that enhances cell immortalisation; E6 codes for 
proteins that inhibit p53, suppressing cell apoptosis; E7 codes for a viral protein that 
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binds to tumour suppressor proteins, thus overriding the control of normal cell 
division and keeping the cell in an unscheduled synthesis-phase (S-phase) state 
(Ramakrishnan et al., 2015; Faridi et al., 2011; Muñoz et al., 2006; Tsai and Chen, 
2003). The ‘late’ genes, L1/L2, code for the structural completion of the final virus 
particles, and the URR (or LCR) controls the regulation of gene expression, promotes 
the replication of the viral genome and its eventual packaging into newly formed virus 
particles (Muñoz et al., 2006). Of these seven genes, E5, E6, and E7, are considered 
critical in the carcinogenesis of cervical cancer (Ramakrishnan et al., 2015).  
1.6 Mechanism of HPV carcinogenesis   
1.6.1 HPV life cycle  
The virus is introduced to the body through a micro trauma at the site of the 
epithelium, possibly from small vaginal tears acquired during sexual intercourse, or 
friction caused by clothing. The infectious cycle begins when HPV particles reach the 
basal layer of the epithelium, and are thought to enter epithelial stem cells, which are 
abundant in hair follicles and may be an important site of entry (Doorbar, 2005). In 
early pre-cancerous lesions (CIN1 and CIN2), the viral DNA is present in episomal 
form, thus replicating independently of the host’s genome (Williams et al, 2011). In 
more advanced pre-cancerous lesions (CIN3) and invasive carcinoma, the viral 
genome integrates with the host’s genome. 
The initial infection promotes a proliferative phase, increasing the number of basal 
cells infected with viral episomes. The viral genome is replicated to a low copy 
number of around 10-200 copies per cell and maintained within the infected, but still 
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functional cells. Proteins coded for by E1/E2 are considered critical for DNA 
replication within the basal layer (Williams et al., 2011). The immune system possibly 
keeps the infection in this state during viral persistence (Doorbar, 2005).  
Normal eukaryotic cell cycle consists of four main stages. G1: the cell is metabolically 
active and growing; S phase: DNA replication takes place; G2: the cell prepares for 
division by synthesising a number of important proteins; and M or mitosis phase: the 
chromosomes are duplicated into sister chromatids, separate into two daughter nuclei 
and the cell divides into two, each new cell containing an exact copy of its parent 
DNA (Cooper, 2000).  
G1, G2 and M phases incorporate key cellular checkpoints. These checkpoints can 
detect unfavourable conditions and prevent the cell from passing on the mutated DNA 
into daughter cells by inhibiting division. Critically in HPV infection, the protein 
products of E5, E6 and E7, interact with a number of cellular proteins that inhibit the 







(OpenStax College, 2013). 
HPV: Human papillomavirus.  
Figure 8. HPV interaction of cell checkpoints, especially G2.
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E5 activates epidermal growth factor receptor (EGFR), stimulating biochemical 
cascades that result in an overexpression of proto-oncogenes and stimulate rapid cell 
growth; E5 can also inhibit the expression of tumour suppressor gene p21 and disturb 
normal cell cycle checkpoints (Tsai and Chen, 2003). Protein Retinoblastoma (pRb) is 
a tumour suppressor protein that can prevent the cell from entering S phase (DNA 
replication) by binding to E2F transcription factor. However, E7 binds to pRb and 
displaces E2F, triggering the expression of proteins necessary for DNA replication 
(Doorbar, 2005). This unscheduled S-phase would normally provoke p53, a cellular 
tumour antigen, to schedule the cell for apoptosis (programmed cell death). However, 
E6 inhibits p53 by targeting it for degradation, thus E6 and E7 co-operate together to 
efficiently ‘hijack’ normal cell activity, abolish normal termination and promote cell 
immortalisation (Faridi et al., 2011).  
As part of their natural turnover, aging basal cells of the epithelium are pushed to the 
parabasal layer and lose their ability to divide. As they breakdown, the low copy 
number of virus particles are released to repeat the infectious cycle (Münger et al., 
2004). The loss of control of cell growth coupled to increasing genomic instability and 
oncogenic mutations, lead to the formation of CIN in the transformation zone of the 
cervix.  
1.7 Classification of cervical intraepithelial neoplasia  
1.7.1 Cervical squamous intraepithelial neoplasia (CIN) 
In 2013, the NHS Cervical Screening Programme (NHSCSP) adopted the revised 
British Society Clinical Cytology (BSCC) terminology into their new guidelines for 
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the classification of cervical cytology (NHS Cervical Screening Programme, 2013). 
Outside of the UK, the Bethesda system is widely used (National Cancer Institute 
[NCI], 2001).  The classification systems used both in the UK and the rest of the 
world is summarised in Table 3. 
Cytology Histology 
NHSCSP 2013  
(UK cytology system) 
Bethesda 2001 (cytology 
system widely used outside of 
the UK) 
Used widely 
throughout the world 
Borderline changes in 





Low-grade dyskaryosis LSIL CIN1 
High-grade dyskaryosis (moderate) HSIL CIN2 
High-grade dyskaryosis (severe) HSIL CIN3 
High-grade dyskaryosis/?invasive SCC HSIL SCC SCC 
ASCUS: Atypical squamous cells of undetermined significance; ASC-H: Atypical squamous cells that 
cannot exclude HSIL; CIN: Cervical intraepithelial neoplasia; LSIL: Low-grade intraepithelial lesion; 
HSIL: High-grade intraepithelial lesion; SCC: Squamous cell carcinoma.  
Table 3. The BAC/NHSCSP and Bethesda systems for classification of CIN.  
The histogenetic classification of pre-cancerous lesions as CIN was introduced in 
1967 by Richart and now widely adopted, reflects the depth of epithelial involvement. 
CIN is identified through histological diagnosis and defined as the amount of 
squamous epithelium that is dyskaryotic or made up of undifferentiated neoplastic 
cells of basaloid type (Buckley et al., 1982). However, other factors also contribute to 
the classification of CIN, including stratification, the site of mitotic figures within the 
epithelium, and the presence of abnormal mitotic figures (Buckley et al., 1982).  
Examination of cervical cells seeks to identify atypical cells, ‘koliocytes’ that have 
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with a clear halo around the nucleus (Figure 9). The halo is thought to be a reflection 
of HPV infection (Edwards, 2015).  
 
Uthman, 2006a 
Figure 9. Normal cervical cells (left) and koliocytes (right). 
An example of low-grade dyskaryosis (Bethesda classification: LSIL) is shown in 
Figure 10, and high-grade dyskaryosis (Bethesda classification: HSIL), together with 
changes visible at the surface of the cervix, is shown in Figure 11.  
 
Uthman, 2007a 





(1); Uthman, 2007b                                                          (2); Honduras Health, no date 
Figure 11. (1) High-grade dyskaryosis (Bethesda classification: HSIL); changes visible at the 
surface of the cervix (2).  
Histological grading of CIN takes into account the level of involvement of the 
epithelium. For CIN1, undifferentiated cells are confined to the lower third of the 
epithelium. Cytological changes may be evident throughout the entire thickness of the 
epithelium but mitotic figures are few, and adequate cell maturation is still evident 
with minimal nuclear abnormalities (IRAC, 2016d). For CIN2, the abnormalities are 
found approximately across one half to two thirds of the thickness of the epithelium. 
Mitotic figures may be evident through the lower half of the tissue and the nuclear 
abnormalities are more prominent. For CIN3, the full thickness of the epithelium is 
usually involved together with abundant mitotic figures, which may have abnormal 
forms. Differentiation and stratification are often absent altogether (Figure 12). 
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           CIN1; Uthman, 2013                              CIN2; Uthman, 2006b                      CIN3: Uthman, 
2006c 
Figure 12. Types of cervical intraepithelial neoplasia (CIN).  
1.7.2 Classification of cervical glandular intraepithelial neoplasia (CGIN) 
Both the NHSCSP and the Bethesda systems (NCI, 2001) have attempted to define the 
range of cellular changes observed in the glandular mucosa (Table 4).    
NHSCSP 2013  
(UK cytology system) 
Bethesda 2001  
(cytology system widely used outside of 
the UK) 
Borderline changes in endocervical cells Atypical glandular cells, not otherwise 
specified 
a. Endocervical  
b. Endometrial 
c. Glandular 
?Glandular neoplasia  
a. ?Glandular neoplasia of 
endocervical type (divided into 
low-grade cervical glandular 
intraepithelial neoplasia [LG-
CGIN], and high-grade cervical 
glandular intraepithelial neoplasia  






NHSCSP 2013  
(UK cytology system) 
Bethesda 2001  
(cytology system widely used outside of 
the UK) 
[HG-CGIN]) 
b. ?Glandular neoplasia (non-
cervical) 
 Endocervical adenocarcinoma in situ 
 Adenocarcinoma  
a. Endocervical 
b. Endometrial 
c. Extra uterine 
d. Not otherwise specified 
LG-CGIN: Low-grade cervical glandular intraepithelial neoplasia; HG-CGIN: High-grade cervical 
glandular intraepithelial neoplasia.  
Table 4. The BAC/NHSCSP and Bethesda systems for classification of glandular neoplasia 
The biology of glandular epithelial lesions is less well understood than squamous 
epithelial lesions. Around 60% of adenocarcinomas are pure and involve only the 
glandular cells, with the remaining 40% composed of both squamous and glandular 
cells (adenosquamous carcinoma); (Kyrgiou, 2013). Adenocarcinomas present with 
more histological sub types than squamous carcinomas.  
Low-grade cervical glandular intraepithelial neoplasia (CGIN) affects the basal two 
thirds of the epithelium, may present as altered glandular profiles, and is characterised 
by hyperchromasia with small changes to nuclear size, increased mitosis and loss of 
polarity (Brown, no date). High-grade CGIN, which includes adenocarcinoma in situ, 
affects the whole depth of the epithelium, where the glands are budded or branched, 
and characterised by hyperchromasia, atypical nuclei and increased and abnormal 
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mitosis. These changes are accompanied by an increased bioavailability of the Ki-67 
protein, a marker for cell proliferation, and the enzyme, mindbomb E3 ubiquitin 
protein ligase 1 (MIB-1) which is involved in the control of apoptosis. 
Since cervical screening collects both glandular and squamous cells, they are often 
present together (Figure 13).  
Halliwell, 2016b 
Sampled from adenocarcinoma Stage 1B1 (unstained) a: High-grade cervical glandular 
intraepithelial cell with atypical nuclei and increased hyperchromasia. b: Cellular debris, possibly a 
stray nucleus on top of cell. c: Low-grade squamous cell; elongated nucleus may be indicative of 
metaphase with chromosomes lined up along the metaphase plate.  
Figure 13. Adenocarcinoma Stage 1B1: mixed grade are often present.
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1.8 Conventional screening for cervical cancer  
1.8.1 National policy 
In the UK, the national policy on cervical screening is divided into two age groups. 
Women aged 25-49 years are invited for routine screening every 3 years, and women 
aged 50-64 are invited for screening every 5 years (Screening and Immunisations 
Team, Health & Social Care Information Centre, 2014). Invasive disease in women 
under 25 years is rare, which prompted a revision in 2003 of the screening starting age 
from 20 years to 25 years. 
For women aged 30 years and under, the prevalence of HPV infection is high, whilst 
the risk of cervical cancer is low; these patients often present with clinically 
insignificant lesions that will regress without intervention (Women’s Health and 
Education Centre, 2010).  
For women aged 65 and over, only women who have never been screened, or those 
who have recently had abnormal tests on three occasions are invited for screening 
(Screening and Immunisations Team, Health & Social Care Information Centre, 
2014), despite evidence that approximately 20% of new cases of cervical cancer occur 
in women aged 65 years or over (The Guardian, 2015), and about half of all deaths 
occur in women in this age group (Sherman et al., 2015).  
The diagnosis of celebrity Jade Goody in 2008 and her subsequent death in 2009 at 
the age of 27 from cervical cancer, prompted an extra 478, 000 screening attendances 
in England between 2008/09; with 28% of these attendances occurring in the 25-49 
age group and whose screening was overdue (Lancucki et al., 2012). The high media 
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attention surrounding Goody’s diagnosis focused much attention on lowering the age 
of first screening, and gave rise to the perception of cervical cancer is a disease 
affecting only younger women (Sherman et al., 2015). As the proportion of the UK’s 
population aged 65 and over is predicted to rise to 24.3% by 2037 (Office for National 
Statistics, 2015), and a significant number will be women, the number of women in 
this age group affected by the disease will also increase. UK policy on cervical 
screening in this age group needs to reflect this pattern of predicted change.  
1.8.2 The Papanicolaou smear 
Originally described by Dr George N Papanicolaou and Dr Herbert Traut (1941), the 
Papanicolaou cervical smear test (Pap smear) was the first method of screening for 
cervical cancer in many countries, and has contributed significantly to reducing 
cervical cancer incidence and mortality by 75% (Mehta et al., 2009). The Pap smear 
collects exfoliated cells scraped from the cervix which are spread directly onto a glass 
slide and viewed microscopically to identify atypical cells (dyskaryosis). However, 
the test has a number of important limitations. Inadequate sampling, which accounts 
for around 8% of samples, occurs when the transformation zone is not sampled 
correctly, and only squamous cells are collected (Mehta et al., 2009). Conventional 
cytology screening is subjective, leading to misinterpretation (Nanda et al., 2000). The 
false-negative rate for the test has been reported as high as 36% (Spence et al., 2007), 
with a reported sensitivity of 30% to 87%, and a specificity of 86% to 100% (Nanda et 
al., 2000). The Pap smear can be compromised by contaminants such as blood, 
bacteria and yeast (Mehta et al., 2009).  
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The Pap smear was originally developed to detect squamous cell carcinomas, and has 
a lower sensitivity for adenocarcinoma (Scheiden et al., 2004). Since a quarter of new 
cases of cervical cancer are adenocarcinomas, the Pap smear will become an 
increasingly less useful diagnostic tool. The most important limitation is human error, 
either through inaccurate observer interpretation or bias, and it has a low sensitivity in 
detecting CIN2 and CIN3 (Boone et al., 2012). The sensitivity becomes more variable 
with age, increasing in women aged 50 years and over (Cuzick et al., 2006). Since a 
typical Pap smear slide contains 50,000-150,000 cells with the possibility of only a 
few being abnormal, it is not surprising that underlying atypia is missed (Mehta et al., 
2009).  
1.8.3 Liquid-based cytology 
In many countries, including the UK, the Pap smear has been replaced by liquid-based 
cytology (LBC) which has greatly reduced the number of inadequate samples 
(Safaeian and Solomon, 2007). This technique uses a cervical speculum that brushes 
cells from the cervix and the speculum is then plunged directly into an ethanol-based 
preservative/fixative and vigorously stirred, producing a suspension of filtered cells 
ready for mounting onto a slide. This sampling technique offers some advantages over 
the conventional Pap smear, including providing a higher number of cells in the media 
and the removal of contaminants such as blood.  
LBC is also semi-automated, provides an even layer of cells that are easier to 
interpret, and can be used for testing for HPV DNA and other biomarkers (Safaeian et 
al., 2007), which removes the necessity for the patient to return for an additional visit. 
LBC has been shown to have comparable sensitivity in the detection of CIN2 or worse 
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lesions compared to the conventional Pap smear but can also produce more positive 
findings leading to a lower predictive value (Ronco et al, 2007).  This higher rate of 
satisfactory LBC smears reduces both the patient’s anxiety and financial costs 
associated with repeat Pap smears (Figure 14). 
 
Continuing Medical Education, 2014 
Figure 14. An example of a LBC slide (left) and a conventional Pap cytology slide (right) after 
staining and mounting. 
1.8.4 HPV testing  
An investigation of HPV testing showed that it was not cost-effective nor did it add 
any significant benefit when used in combination with LBC; however, it was shown to 
be highly effective as sole primary screening method reported to provide 60-70% 
better protection against invasive cervical cancer when compared with LBC 
 31 
 
(Kitchener et al., 2009). HPV testing has other advantages over LBC in terms of a 
high negative predictive value and is based on fully automated platforms enabling 
high throughput. In the UK, it is likely that HPV-based screening will eventually 
replace LBC screening and may optimise the screening interval to 5 years for women 
aged 30 years and above (Kyrgiou and Shafi, 2014).   
1.9 Alternative screening approaches  
1.9.1 Infrared biospectroscopy  
Infrared (IR) radiation was discovered in 1800 by Sir William Hershel and most IR 
instruments were at that time dependent on prisms or grating monochromators. Albert 
Michelson developed the interferometer in 1881 and by 1949; Peter Fellgett obtained 
the first IR spectrum by using a Fourier-transform IR (FTIR) spectrometer. ‘Fellgett's 
advantage’ as it became known, improved the signal-to-noise ratio by means of the 
simultaneous measurement at different wavelengths (Fellgett, 1949). By the 1960’s, 
FTIR spectrometers became commercially available, and in 1965, an algorithm was 
developed to quickly compute a Fourier transform (Cooley and Tukey, 1965). Since 
then, FTIR spectroscopy has greatly improved the quality of IR spectra and reduced 
the operational time in gathering spectral data. Today, depending upon the machine’s 
settings, a single Fourier-transform spectrum can be obtained in as little as ~30 
seconds.  
1.9.1.1 Infrared-active and infrared-inactive molecules  
Infrared spectroscopy exploits the light properties of a specific part of the 
electromagnetic spectrum (Figure 15), which is composed of 7 main types of 
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radiation: gamma rays, X-rays, ultraviolet, visible light, infrared, microwaves and 
radio waves. The IR part of the spectrum is longer in wavelength and lower in 
frequency than visible light and is divided into 4 main regions: the near IR region 
(~14286 to ~7143 cm-1); the shortwave IR region (~7143 to 4000 cm-1); the mid IR 
region (~4000 to 400 cm-1); and the far IR region (< ~400 cm-1). 
 
National Aeronautics and Space Administration (NASA), 2007 
Figure 15. The electromagnetic spectrum. 
When exposed to frequencies within the mid-IR spectrum (4000-400 cm-1), biological 
materials vibrate with distinct frequencies that can be detected. For a molecule to be 
IR-active, a change must occur in the permanent electric dipole moment of the 
molecule that is non-zero as the bond expands and contracts as result of being flooded 
with IR light. This is called the ‘selection rule’ for infrared spectroscopy (Stuart, 





Figure 16. Potential changes in the dipole moments of a heteronuclear molecule.  
By contrast, an example of an IR-inactive molecule is a mononuclear diatomic 
molecule, where molecules are composed of only one type of element such as O2, and 
where the bond is symmetrical and IR light has no effect on the dipole moment 
(Figure 17).  
 
Halliwell, 2016d 
Figure 17. An example of an IR-inactive molecule. 
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This molecule has no permanent dipole, has only a single motion and therefore its 
dipole moment will always remain at zero no matter how long the bond.  
1.9.1.2 Vibrational modes of biological materials  
The atoms in a polyatomic molecule are in constant motion causing the molecule to 
undergo translational and rotational motions, known as ‘normal modes’. Atoms in 
molecules can also move relative to each other, promoting changes in bond length or 
move out of their current plane. These stretching and bending movements of 
molecules irradiated with IR light are collectively referred to as ‘vibrations’ (Stuart, 
2004). Some vibrations are due to bonds stretching in-phase (i.e., symmetrical 
stretching) or out-of-phase (i.e., asymmetrical stretching); other bending vibrations 
can also occur that add to IR spectra and including rocking and scissoring (Figure 18).  
 
 
UC Davis ChemWiki, no date 
Figure 18. Potential vibrations that can contribute to infrared spectra. 
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The degrees of freedom for a polyatomic molecule containing many atoms (N) are 
governed by whether it is a linear or non-linear molecule. For both types of molecule, 
the degrees of freedom describe the translational, rotational, and vibrational motions 
of the molecule around the three Cartesian axes: x, y, and z (i.e., 3N degrees of 
freedom). A linear molecule can only rotate around 2 of the Cartesian axes whilst a 
non-linear can rotate around all three. Obtaining the vibrational degrees of freedom 
for molecules is performed by subtracting the number of translational and rotational 
degrees of freedom from the number of atoms in the molecules (Table 5).  
Types of degrees of freedom Linear  
(Example:  




Number of atoms  3 5 
Translational  3 3 
Rotational  2 3 
Vibrational 3N - 5 3N - 6 
Formula  3N = (3 x 3 – 5) 3N = (3 x 5 – 6) 
Total number of vibrational modes 4 9 
Table 5. Calculating the degrees of freedom for polyatomic molecules. 
A common unit used to present data collected at spectral regions include the 
‘wavelength’ expressed as metres or microns (e.g., 1 µm = 10-6 m) and are typically 
used by physicists. For spectroscopists, the ‘wavenumber’ is the preferred unit of 
choice and is the number of waves in a length of one centimetre: 
Ṽ = 1/λ = ν/c 
The wavelength unit (cm-1) is used extensively in the following chapters. 
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1.9.1.3 Biospectroscopy and cancer studies   
The application of Fourier-transform biospectroscopy to cancer cytology and 
histology is a rapidly expanding area of research (Bellisola and Sorio, 2012; Diem et 
al., 2004). Since the rapid synthesis of proteins, lipids and nucleic acids is a condition 
for the proliferation of cancer cells (Baenke et al, 2013), changes in these biomarkers 
can be detected by infrared spectroscopy.  
The most important spectral regions of biological interest are found within the 
biochemical ‘fingerprint region’ (1800 cm-1 to 900 cm-1); (Purandare et al., 2013), and 
contain features specific lipids, DNA, polypeptides (as suggested by bonding types 
amide I and amide II), glycomaterials and collagen (Table 6); (Movasaghi et al., 
2008). As the bioavailability of these biomarkers increases or decreases, the area 
under the curve of a peak associated with the relevant wavenumber within a spectrum 
will increase or decrease accordingly, and can be quantified by IR spectroscopy to 
reveal important patterns in intracellular change (Griffiths and De Haseth, 2007). 
Tentative assignment of biomarkers to wavenumbera Wavenumber (cm-1) 
Lipids, fatty acids ~1750 
Amide I – predominantly in α helix formation ~1651 
Protein Amide II – predominantly β sheet ~1550 
Methylene chains in lipids ~1470 
Phosphate I - asymmetric (DNA)  ~1223 
C-O bands from glycomaterials and proteins ~1169 
Phosphate I  - asymmetric (DNA) ~1072 
Glycogen & collagen ~1030 
a Movasaghi et al, 2008; N.B.: other biomarkers may also be associated with wavenumbers.  
 Table 6. Tentative assignment of important biomarkers.  
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Of the three main forms of FTIR-spectroscopic sampling modes (transmission, 
transflection and attenuated total reflectance/reflection [ATR]); (Baker et al., 2014), 
this dissertation focuses on the proven advantages of the application of attenuated total 
reflectance, Fourier-transform infra-red (ATR-FTIR) spectroscopy to cervical 
cytology. ATR-FTIR spectroscopy has demonstrated advantages over 
conventional cervical cytology screening, proving to be an inexpensive and 
robust method. Previous research has shown this technique is able to segregate 
grades of cervical cytology (Purandare et al., 2014), classify cervical cytology 
based on HPV infection with low- or high-risk types and according to the 
patient’s age (Lima et al., 2014), and diagnose underlying disease more accurately 
that conventional cytology screening (Gajjar et al., 2014).  
Other applications of ATR-FTIR include being used to differentiate the different 
stages of the cell cycle (Stuart, 2004), complement histological classification of skin 
cancer (Lima et al., 2015), detect the recurrence of bladder from bladder wash (Gok et 
al., 2016), and  differentiate brain tumours, including severity and organ of metastatic 
disease, from human serum (Hands et al., 2016).  
1.9.1.4 Spectral acquisition  
Detailed instructions for spectral acquisition are given in Project One, and the 
laboratory protocol for the preparation of liquid-based cervical cytology 
samples in provided in Appendix C.  
1.9.1.5 Pre-processing of raw spectra  
Pre-processing aims to correct problems associated with spectral data 
acquisition, thereby improving the robustness and accuracy of any subsequent 
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multivariate analysis by data mining relevant features and removing redundant 
data (Lasch, 2012). A typical spectrum collected by ATR-FTIR spectroscopy 
contains 32 scans collecting some 235 data points. The result is a very large 
array of absorbance which is difficult to work with and extract meaningful 
outcomes. Following initial visual inspection of the raw spectra to identify 
errors (e.g., mounting the sample onto the wrong slide of the slide, which will 
produce spectra specific to glass and show as a distinctive ‘quiff’ to the far 
right), feature selection is applied and the spectra are cut to the ‘fingerprint 
region.’ This process discards irrelevant data that lies outside the region of 
interest. A baseline correction is then applied to the cut spectra, followed by a 
normalisation technique (Table 7).  
Baseline correction techniques Normalisation techniques 
Rubber-band correction Normalise to Amide I/II or other (including Vector) 
1st Order Differentiation correction Normalise to Vector 
2nd Order Differentiation correction Normalise to Vector 
Table 7. The options for pre-processing of spectra and application of PCA-LDA following pre-
processing.  
Rubber-band baseline correction is based on the idea that a spectrum is divided 
into n ranges (n = number of baseline points) of equal size. The minima y-value 
of each baseline is determined. Connecting the minima with straight lines 
creates a baseline. Starting from below the baseline, a rubber-band is stretched 
over this curve, making it the baseline. Any points that do not lie on the rubber-
band are discarded.  
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The application of differentiation as a baseline correction serves to segregate 
the gradients of spectral bands, making them more prominent (Trevisan et al., 
2012). First-order differentiation is the most widely used, although second-
order differentiation can also be used. The limitation of this approach is that 
with each successive order of differentiation, the method augments any spectral 
noise by one order of magnitude (Griffiths and Haseth, 2007).  
Differences in sample thickness or concentration can contribute a significant 
amount of spectral variation between samples. Normalizing to Amide I, Amide 
II, etc, forces all spectra to have the same absorbance intensity at the Amide I/II 
peaks (Baker et al., 2014). The disadvantage of normalising this way is that any 
changes at peaks associated with Amide I/II may be disguised. Vector 
normalisation (formally referred to as Euclidean), is the preferred choice as it 
will not disguise changes in biologically important peaks. It is the only 
available normalisation technique application following 1st and 2nd Order 
differentiation.   
Normalising is critical to allow us to make data comparable. Without it, the data 
will remain distorted. The technique assists in compensating for differences in 
sample quality. The choice of baseline and normalisation approaches should be 
based upon the characteristics of each data set (Trevisan et al., 2012) and for 
this reason, the spectra should be initially explored comparing several 
techniques to determine the method that best suits the data.    
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1.9.1.6 Multivariate analysis  
Multivariate analysis is the statistical technique used to analyse data that arises from 
more than one variable. Once the spectral datasets have been baseline corrected and 
normalised, multivariate analysis techniques such as Principal Component Analysis 
(PCA) and Linear Discriminant Analysis (LDA), can be applied to reduce a large 
number of data into small data sets or clusters, making them easier to compare.  
1.9.1.7 Principal Component Analysis and Linear Discriminant Analysis 
PCA is an unsupervised technique commonly used as the first step in analysing large, 
multivariate data sets. Unsupervised techniques require no information from the user 
but rely instead on an internal criterion to guide learning. In unsupervised learning, the 
system forms clusters (groupings, regions of data space). In general terms, PCA 
reduces the dimensionality of large data sets and using mathematical projection, the 
original data set which may have involved many variables, can often be interpreted in 
just a few variables (the Principal Components; PCs). This reduced dimensional data 
set will allow the user to spot trends, patterns and outliers in the data, far more easily 
than would have been possible without performing the PCA. When applied to spectra, 
PCA identifies common sources of variance across spectra and collates them into a 
small number of dimensions. PCA is often not enough to segregate out data classes or 
clusters sufficiently, since the heterogeneity within the data is often due to within-
class variability rather than between-class variability. Since PCA is unsupervised and 
has had no instruction from the user, it cannot distinguish between these sorts of 
variability (Martin et al., 2010). By applying a supervised technique such as LDA to 
the PCA output, it promotes inter-class variation to be identified whilst preventing 
over-fitting of the data.  
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LDA is supervised technique because it takes into account the nomination of classes 
determined by the user. It is a generalization of Fisher's linear discriminant, a method 
used in statistics, pattern recognition and machine learning, to find a linear 
combination of features that separates two or more classes of objects or events. The 
resulting combination may be used as a linear classifier or, more commonly, for 
dimensionality reduction before later classification. LDA works when the 
measurements made on independent variables for each observation are continuous 
quantities.  
1.9.2 Alternative infrared techniques 
1.9.2.1 Scanning near field optical microscopy coupled to free electron laser  
Although ATR-FTIR spectroscopy has proven advantages over conventional cervical 
cytology screening, it is limited in spatial resolution by the effect of diffraction. 
Diffraction describes the phenomenon of the bending of light waves around obstacles 
in its path causing it to spread out. This effect restricts the spatial resolution of ATR-
FTIR spectroscopy to about half the wavelength of light or ~3 µm to 30 µm (Harrison 
et al., 2013). Resolution is a measure of how closely the lines of an image can be 
resolved (i.e., the number of independent pixels per value per unit length).  
The nanoscopic technique of scanning near field optical microscopy (SNOM) has 
shown  promise in providing detailed information on cell topography and cytoplasmic 
structures. SNOM has a clear advantage over conventional infrared IR microscopy in 
terms of spatial resolution because it is able to overcome the diffraction limit, by 
employing an apertured fibre optic scanning tip. However, the SNOM technique 
requires relatively high photon intensities such as those provided by an IR free 
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electron laser (IR-FEL) which allows the simultaneous collection of topography and 
optical features at scales not normally achieved with conventional IR techniques to 
produce high quality, chemically-rich images at designated wavelengths with a spatial 
resolution of ≥0.2 µm (Smith et al, 2013; Cricenti et al., 2002).   
The IR-FEL on the ALICE accelerator at Daresbury Laboratory (Warrington, UK) is 
tuneable over the range of 5.5 µm to 8.8 µm (~1818 cm-1 to ~1136 cm-1), which 
includes a number of biologically important biomarkers as previously mentioned (see 
Table 6), at designated wavenumbers (Movasaghi et al., 2008). Many of these 
biomarkers have previously been used to separate normal, low- and high-grade 
dyskaryosis and cancer cells from each other (Gajjar et al., 2014). 
SNOM has been used to investigate the localisation of molecules within cell 
membranes of prostate cancer cells (Walker et al., 2012). Further research 
demonstrated SNOM can accurately define both the cell surface and internal 
structures in both healthy and anomalous sperm, including the acrosome, nucleus and 
the organisation of mitochondria in the mid-piece region of the tail (Andolfi et al., 
2015). Furthermore, it has demonstrated the potential for single molecule imaging 
(Zhong et al., 2008).  
The application of SNOM to oesophageal cancer tissue studies provided evidence of 
its potentiality for cancer diagnosis (Smith et al, 2013). The increased spatial 
resolution of SNOM has the potential to reveal and quantify highly localised cancer-
related changes in cervical cells at the sub-cellular level (1 - 0.1 µm), and more 
accurately and precisely than conventional IR techniques. The majority of the above 
described IR-SNOM-FEL studies were all carried out in reflection mode.  
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This dissertation reports the collection of data obtained using a SNOM-IR-FEL in 
transmission mode at the ALICE facility in Daresbury, Warrington, to image whole 
cervical cells. The experimental period ran from February to May 2015 ( Project 
Two). The set-up of the SNOM-IR-FEL used to collect data for this project is 






    IR: Infrared; SNOM: Scanning near-field optical microscopy. CaF2: Calcium fluoride: MCT: Mercury Cadmium Telluride (HgCdTe); SNOM: Scanning near-field 
optical      
   microscopy. 
Used with kind permission from Dr M.R.F Siggel-King (Department of Physics, Liverpool University), 2016 
Figure 19. Schematic of SNOM-IR-FEL set-up used to conduct Project Two. 
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1.10 Treatment approaches for pre-malignant CIN 
In the UK, the choice of treatment for pre-malignant CIN takes into account both the 
level of dyskaryosis and the histological classification of CIN (Cancer Research UK, 
2014c). Ablative techniques, such as laser therapy and cryotherapy, destroy abnormal 
cells at the surface of the cervix, allowing normal cells to re-populate the treated area. 
Excisional treatments to remove the area of the transformation zone that contains 
abnormal cells that could develop into cervical cancer, include cold knife conisation, 
laser conisation and large loop excision of the transformation zone (LLETZ). Since 
LLETZ offers many advantages including low cost, high success rate and ease of use 
(Carcopino et al., 2013), it is the preferred treatment in most countries. Local 
conservative treatments for pre-invasive CIN are highly effective in preventing 
recurrent cervical disease and future invasion (95% or better, with the exception of 
cryotherapy which has a lower clearance rate of 85%); (Wai and Patil, 2008). 
The LLETZ technique involves using a wire loop, available in different sizes, through 
which an electrical current is passed. The loop is applied to the transformation zone of 
the cervix to a depth of around 7-8 mm and extending 4-5 mm beyond the lesion 
itself; the transformation zone can vary in size and shape, but for most patients, the 
entire zone can be removed by a loop 2 cm in diameter and 1.5 cm in depth 






LLETZ: large loop excision of the transformation zone.  
Used with kind permission from Jo’s Cervical Cancer Trust, 2016  
Figure 20. The LLETZ procedure.  
However, there is a substantial amount of evidence to suggest that excisional 
treatment is coupled to a significant risk to future pregnancies, including preterm birth 
and mid-trimester loss (Kyrgiou et al., 2015a; Kyrgiou et al., 2015b; Kyrgiou et al., 
2014; Arbyn et al, 2008; Kyrgiou et al., 2006). Further research also found that 
women with a shorter time interval between excision treatment and subsequent 
pregnancy, have an increased risk of spontaneous abortion (Connor et al., 2013).  
Removal of part of the cervix may undermine the mechanical integrity of the cervix as 
a result of collagen disruption (Stout et al., 2014; Phadnis et al., 2011). Additionally, a 
function of the endocervical glands is to produce the mucus plug during pregnancy, 
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which has antimicrobial properties against Gram positive and negative bacteria; thus 
their removal may damage the host defence mechanism against ascending infections 
when pregnant (Hein et al., 2001). The length of cone removed is directly correlated 
to the frequency and severity of the adverse events (Kyrgiou et al., 2015a).  
Pre-treatment cervical length and dimensions vary amongst women (Kyrgiou et 
al., 2015a), as does the does the volume of cervical tissue excised. The 
assessment of the proportion (percentage) of excised cervical tissue may 
correlate more accurately to the chances of adverse sequelae than the absolute 
dimensions (i.e., cone depth and volume), and therefore provide a clinical cut-
off that signifies women at risk (Arbyn et al., 2014; Khalid et al., 2012; 
Kyrgiou et al, 2012., Founta et al., 2010).   
Given that ATR-FTIR spectroscopy is able to detect underlying disease more 
accurately than conventional cytology (Lima et al., 2014), the ‘biochemical 
fingerprint’ produced for normal or dysplastic cells, and cells before and after 
treatment, may differ based on changes in availability of lipids, proteins, 
carbohydrates and so on. This may arise from altered biochemical processes as 
a result of excision or treatment of the disease. 
1.11 Aims and objectives  
This research project was conducted via two studies using samples from the 
same cohort of patients. Both studies involved using whole cervical cells 
collected from women attending colposcopy. The objectives of each study are 
given below.  
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1.11.1 Project One objective 
The aim of this study was to assess the impact that local treatment may have on 
the cervix by comparing the spectral absorbance within the ‘fingerprint region’ 
of cervical cells before and after treatment, and to evaluate how these changes 
may be affected by the absolute cone dimensions or the proportion (percentage) 
of cervix excised. 
1.11.2 Project Two objective 
The aim of this pilot study was to assess the potential of SNOM in combination with 
an IR-FEL in the detection of the biophysical properties of cervical cell abnormalities. 
Spectra were also collected using traditional ATR-FTIR biospectroscopy to 
investigate the differences between the techniques. 
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2 Project One 
This paper is to be submitted for publication to Nature Communications as: 
 “Tracking the Impact of Excisional Cervical Treatment on the 
Cervix using Biospectroscopy.” 
Diane E. Halliwell, Maria Kyrgiou, Anita Mitra, Ilkka Kalliala, Evangelos 
Paraskevaidis, Georgios Theophilou, Pierre L. Martin-Hirsch and Francis L. Martin. 
 
Contribution:  
I collaborated with the co-authors on this project by preparing the samples for spectral 
acquisition; obtaining the spectra; pre-processing of the spectra and applying 
multivariate analysis; performing the statistical comparisons of the spectra; extracting 
the demography of the patient population; and helping to prepare the manuscript for 
publication.  
 
…………………………………  ………………………………………… 
Diane E. Halliwell     Professor Francis L. Martin 
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Local excisional treatment for cervical intra-epithelial neoplasia (CIN) is linked 
to significant adverse sequelae including preterm birth, with cone depth and 
radicality of treatment correlating to the frequency and severity of adverse 
events. Attenuated total reflectance Fourier-transform infra-red (ATR-FTIR) 
spectroscopy can detect underlying cervical disease more accurately than 
conventional cytology. The biochemical ‘fingerprint’ produced for cells before 
and after treatment may differ as a result of altered biochemical processes due 
to excision, or treatment of the disease. Since pre-treatment cervix length vary 
amongst women, the percentage of cervix excised may correlate more 
accurately to risk than absolute dimensions. We show that treatment for CIN 
significantly alters the biochemical fingerprint in the cervix, compared with 
women who have not had treatment; this is due to the excision of cervical tissue 
rather than a disease controlling effect. However, the spectra do seem to 
correlate to the cone depth or proportion of cervical length excised. Future 
research should aim to explore the impact of treatment on the biochemical 
‘fingerprint’ in a larger cohort.  
 
Keywords: cervical intraepithelial neoplasia, CIN; preterm birth; excisional 
treatment; LLETZ; biospectroscopy; biochemical fingerprint 
  
 Nature Communications 
Page 3 of 46  
 
The introduction of systematic call and recall screening programs in the UK 
over the past 20 years has resulted in a profound decrease in the incidence and 
mortality from invasive cervical cancer, since pre-invasive lesions (cervical 
intra-epithelial neoplasia; CIN) can be detected by the screening program and 
treated appropriately1,2. The choice of treatment technique varies across 
countries, although outpatient large loop excision of the transformation zone 
(LLETZ) is the preferred treatment in most. This preference is because LLETZ 
offers many advantages including low cost, high success rate and ease of use.3 
The mean age of women undergoing treatment for pre-invasive cervical 
disease is similar to the age of women having their first child. Although local 
conservative treatments for pre-invasive cervical lesions are highly effective in 
preventing recurrent cervical disease and future invasion2, there is mounting 
evidence that excisional treatment is associated with a significant risk to future 
pregnancies, including preterm birth and mid-trimester loss4,5,6. It has been 
postulated that removal of part of the cervix possibly leads to acquired 
mechanical weakness as a result of collagen disruption7,8. Furthermore, 
endocervical glands produce the mucus plug during pregnancy which has 
antimicrobial properties against Gram positive and negative bacteria; thus their 
removal may damage the host defence mechanism against ascending infections 
when pregnant9.  
The cone depth and radicality of treatment have been found to be directly 
correlated to the frequency and severity of the adverse events10. Given that the 
pre-treatment cervix length and dimensions vary amongst women11, it is 
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biologically plausible that the proportion (percentage) of the cervix excised may 
more accurately correlate to the chances of adverse sequelae than the absolute 
dimensions, and that there may be a cut-off for the proportion of excision that 
signifies women at risk12,13,14,15.  
Attenuated total reflectance Fourier-transform infra-red (ATR-FTIR) 
spectroscopy has shown potential in the field of cancer screening, being an 
inexpensive but robust technique. Previous research demonstrated that the 
technique is able to segregate grades of cervical cytology16,17, classify cervical 
cytology based on HPV infection with low- or high-risk types18, and diagnose 
underlying disease more accurately that conventional cytology screening19. 
Infra-red (IR) spectroscopy exploits the molecular vibrations of biologically 
active molecules that are created by dipole moments as a result of being flooded 
with IR light. The ‘biochemical fingerprint’ produced for normal or dysplastic 
cells, and cells before and after treatment may differ based on changes in 
availability of lipids, proteins, carbohydrates and so on. This may arise from 
altered biochemical processes as a result of excision or treatment of the disease. 
The aim of this study was to assess the impact that local treatment may have 
on the cervix by comparing the spectral absorbance within the ‘fingerprint 
region’ of cervical cells before and after treatment, and to evaluate how these 
changes may be affected by the absolute cone dimensions or the proportion 
(percentage) of cervix excised. 
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Results 
We enrolled a total of 58 women planned to undergo cervical treatment into the 
study and 27 healthy controls (cytology negative); 20 of these were also HPV 
test negative. Out of the 58 treated women, 34 women had paired samples 
before and after treatment and 58 had at least post-treatment samples; 39 out of 
these 58 women had normal results post-treatment (cytology and HPV DNA 
test negative). The depth of the excised cone was available for all 58 women 
who underwent treatment and the proportion of cervical length removed 
available for 53 of these (91%). The different clinical groups are described in 
Figure 1.  
Out of the 34 women with paired samples before and after treatment 
(Comparison 1), 3 samples pre- and 1 sample post-treatment did not provide 
reliable spectra, allowing 29 and 33 samples for analysis, respectively. There 
were no major differences between the pre- and post-treatment samples. The 
rate of women who had sexual intercourse less than 48 hours from the sample 
collection was 90% and 85%, at pre- and post-treatment sampling, respectively 
(p=0.71). None of the patients reported the use of vaginal douching. 
Thirty-nine out of 58 women that had at least a post-treatment sample were 
normal with negative cytology and a negative HPV test post-treatment. The 
characteristics of this subgroup (n=39) were largely similar to the normal 
healthy controls (cytology/HPV test negative) that have had no local cervical 
treatment (n=20); (Comparison 2). The mean age (SD) for treated and control 
groups was 30.8 years (4.5), and 30.6 years (4.2), respectively. The rate of 
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women who were current smokers was significantly greater in the treated group 
(31%), compared with controls (5%); (p=0.04), as was the proportion of women 
taking combined oral contraceptives (51% vs 15% respectively, p=0.01). Fewer 
controls were of Caucasian race (55% vs 77%), and a greater proportion of 
women in the treated group had been sampled in the luteal phase (54%) 
compared with controls (30%), although neither of these differences however 
were statistically significant. The proportion of women reporting recent 
intercourse (75% vs 87%), with bacterial vaginosis diagnoses on high-vaginal 
swabs (10% vs 8%) and vaginal pH was also comparable between the control 
and treated group.  
A total of 58 women had data on the cone depth and proportion of depth 
excised; of these 5 were lacking data on the percentage of excision but had data 
on the depth. Mean depth (SD) of excision for the 58 women was 10.41 mm 
(3.8 mm); (range 2 – 17 mm), and the mean proportion of excision (SD) in the 
53 women for whom this data was available was 29.13% (9.9%); (range 2% – 
56%). Seven of the 58 treated women (12%) had involvement of the cone 
margins at histopathological analysis; 6/58 (10%) with HSIL and 1/58 (2%) 
with LSIL, however, only two of these 7 patients (3%) had abnormal cytology 
at 6 month follow-up. The characteristics of this group were overall similar to 
healthy controls with normal cytology irrespective of HPV status (n=27); 
(Comparison 3); (Table 1 and Supplementary Table 2).  
Once again the proportion of women using combined oral contraceptive pills 
was significantly greater in treated women (48% vs 15%, p=0.003), and a 
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higher percentage of women in the treated group had been sampled in the luteal 
phase (50%) compared with controls (26%), which did not reach statistical 
significance. The groups were otherwise similar with respect to age, ethnicity, 
smoking, parity, recent intercourse, vaginal pH, bacterial vaginosis and HPV 
DNA status. 
Treatment for CIN significantly changes the biochemical fingerprint in 
the cervix, compared with women who have not had treatment. When we 
compared the absorbance spectra before and after local excisional cervical 
treatment, we detected a statistically significant difference between the pre- and 
post-treatment paired samples (p<0.0001; 95 CI = -0.17 to -0.08; Fig. 2 [a]). A 
significant positive rate of change was found for absorbance associated with 
lipids (p=0.0015), and for glycomaterials/proteins (p=0.0006) for the pre-
treatment samples as compared to the post-treatment samples, indicating higher 
bioavailability in the former group (Fig. 2 [b]). A significant positive rate of 
change was found for absorbance associated with proteins featuring amide I 
(p=0.034) and amide II (p=0.0004) type bonding for post-treatment samples as 
compared the pre-treatment ones, indicating higher bioavailability of 
polypeptides in the post-treatment group. A significant negative rate of change 
was detected for absorbance associated with glycogen/collagen (p=0.0008) and 
symmetric phosphate of DNA (p=0.0001) in pre- as opposed to the post-
treatment group, signifying lower bioavailability in the pre-treatment group. 
Similarly, absorbance associated asymmetric phosphate for DNA was shown to 
have a significant negative rate of change for post- as opposed to pre-treatment 
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samples (p=0.0001); (Fig. 1[b]). The steps for pre-processing, multivariate 
analysis and extraction of wavenumbers are summarized in Supplementary 
Figures 1, 2 and 3.  
Changes in the biochemical fingerprint are due to the excision of cervical 
tissue rather than the removal of the disease. In order to explore whether the 
observed differences before and after treatment were attributed to the treatment 
rather than the removal of a disease, we performed a subgroup analysis 
comparing all women that had at least one post-treatment sample with negative 
cytology and HPV DNA test (n=39) versus healthy controls negative for 
cytology and HPV (n=20). We found that the difference in the spectra post-
treatment remained significant, evidencing that the difference observed before 
and after treatment was due to treatment intervention rather than the treatment 
of the disease (p<0.0001; 95% CI = -0.18 to -0.07; Fig 3 [a]). A significant 
positive rate of change was found for absorbance associated with proteins 
featuring amide II bonding (p=0.001) in the treated group compared with 
controls; no other significant changes were detected (Fig. 3 [b]).  
Spectra do not seem to correlate to the cone depth or proportion of 
cervical length excised. We further assessed whether the observed difference 
in the absorbance spectra correlated to the depth of the cone and the proportion 
of the depth excised in the pre-specified treated groups and compared these to 
healthy controls that were cytology negative irrespective of HPV status (n=27). 
We found overall that the spectra of treated women were different to the spectra 
of healthy controls but this did not seem to correlate to the cone depth and 
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proportion of cervical length excised. More specifically, we detected 
statistically significant differences in the spectra when the healthy samples was 
compared to samples from treated patients with a cone depth of <10 mm 
(p=0.0008; 95% CI = 0.03 to 0.12), a cone depth of ≥ 15 mm (p=0.001; 95% CI 
= 0.03 to 0.15), but not for a cone depth between 10-14 mm (Fig. 4 [a]). A 
significant positive rate of change was observed for absorbance associated with 
proteins featuring amide II bonding for both the <10 mm and ≥ 15 mm groups 
compared to healthy samples (p=0.004, p=0.0004, respectively). Cone depth ≥ 
15 mm also had a significant positive rate of change for absorbance associated 
with polypeptides featuring amide I bonding (p=0.008), and a significantly 
negative rate of change for asymmetric phosphate of DNA (p=0.0009) as 
compared to healthy controls (Fig. 4 [b]).  
The results were similar when we correlated the spectra to the percentage of 
excision. The group of women that had <10% of their cervix excised included 
only 2 patients and was therefore excluded from the analysis. For all the 
remaining groups, we detected significant differences as compared with healthy 
cervix [11-20% (p=0.002, mean rank difference = 31.11); 21-30% (p=0.03, 
mean rank difference = 17.85); 31-40% (p=0.007, mean rank difference = 
23.33); and for >40% (p=0.023, mean rank difference = 27.24)]; (Fig. 5 [a]). A 
significant positive rate of change in absorbance associated with biomarkers 
was found only for 11-20% compared with healthy cervix (lipids: p=0.008) and 
polypeptides featuring amide II bonding (p=0.003); (Fig. 5 [b]).  
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The in-between group comparisons of the absorbance spectra demonstrated 
significant differences for most comparisons, apart from, rather surprisingly, the 
comparison of the most extreme values (<10 mm with >=15 mm). Most of the 
comparisons between the clinical groups of the proportional cervical length excised 
did not show a significant difference. (Supplementary Figures 4 and 5). 
The high variability of polypeptides featuring amide I bonding appeared to 
be consistent across untreated, treated and healthy controls, suggesting it is 
unlikely to be due to human sampling error (either through collection of liquid-
based cytological samples or acquisition of spectra), and may suggest that 
synthesis of these molecules is independent of disease status.  
Discussion 
Local conservative treatment for CIN has been associated with significant 
adverse sequelae in subsequent pregnancies4,5,6. The frequency and severity of 
these effects seem to correlate directly to the radicality and depth of the 
treatment10. 
The analysis of the biochemical fingerprints obtained from samples collected 
from the cervix before and 6 months post-treatment revealed that excision of 
cervical tissue and endocervical glands impact on the absorbance spectra that 
appeared to be significantly different after treatment. The significant increase in 
polypeptides in the post-treatment group, as evidenced by amide I/II bonding, 
may be a response to localized injury caused by the excisional treatment. 
Normal wound healing is typified by three overlapping phases; the 
inflammatory phase, the proliferation phase and the maturation phase20,21. At 
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around 30 days following the initial injury and when the wound is closed, the 
maturation phase begins and cellular activity diminishes, the number of blood 
vessels regress and collagen is remodelled from type III to type 1. Although 
previous work has shown that cervical regeneration is almost complete 6 
months after excisional treatment22, our findings suggests that cellular function 
remains elevated at this time point. The presence of scar tissue at the site of 
injury may account for the increased polypeptides, since collagen is composed 
of three separate polypeptide chains23, and production is increased 2-3 times 
more in fibroblasts isolated from scar tissue than from normal tissue24. Despite 
this, a healed wound will only achieve a maximum of 80% of the tensile 
strength of normal epithelium. Further follow up may have shown the 
differences resolve with time or, the distinction is a true reflection of the newly 
formed epithelium capping the original wound. Additionally, the number of 
endocervical cells collected in post-LLETZ liquid-based cytology samples has 
been shown to be significantly decreased25. Therefore, any changes in 
biochemical function following treatment are likely to be a reflection of the 
cellular function largely associated with squamous cells.    
When the spectra in healthy controls post-treatment were compared to 
healthy untreated controls, the differences remained significant, suggesting that 
it is the treatment rather than the excision of the disease that alters the 
biochemical balance within the cervix. Cervical regeneration is dependent upon 
the depth of excision, the percentage of cervix excised and/or the remaining 
cervical tissue immediately after treatment26. Our findings show that patients 
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who were classified as cytologically free of cervical abnormality and HPV 
negative, remained biochemically distinct from healthy controls, with an 
increase in polypeptides (amide II bonding) remaining elevated in the treated 
group, which may be due to the previously hypothesized causes.  
When the absorbance spectra were assessed for different treatment cone 
depths and proportions of cervical lengths excised, we found no direct influence 
of the different clinical groups on the spectra, although the number of samples 
was small in each group. 
The mechanism behind the high variability associated with the production of 
polypeptides that appears to be independent of disease status is unknown, and 
may be a reflection genetic variation or other patient-specific characteristics.    
Several reports have assessed the impact of cervical excision on subsequent 
clinical reproductive outcomes; others suggested that it is the presence of the 
pre-cancer itself that also contributes to the adverse sequelae27. It is likely that 
excision of cervical tissue causes a disruption of the immune defence 
mechanisms, the natural production of antimicrobials and the mucus secretion 
from endocervical glands. These changes together with alterations caused by 
the disease are likely to interact with genetic, viral and microbial factors in a 
complex interplay within the vagina28,29.  
This is the first report that assessed the impact that local excisional treatment 
for cervical pre-invasive disease has on the biochemical fingerprint and 
molecular processes within the cervix. We were able to show that excision 
causes major alterations in the cervico-vaginal environment and further research 
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should establish the pathophysiological processes that may be correlated to 
adverse obstetric sequelae. We did not identify direct correlation of the changes 
to the radicality of the excision measured by cone depth and cervical proportion 
excised, but the numbers in each group were small and the results should be 
interpreted with caution. Further research should explore in more detail the 
impact of the severity/grade of CIN and/or presence of HPV infection on the 
biochemical spectra and should further describe the biochemical alterations in 
treated individuals with or without positive cytology and/or HPV infection post-
treatment in larger cohort. This will allow a more comprehensive exploration of 
the impact of treatment; this was not feasible in this analysis as the number of 
samples in these subgroups was small for any valid comparisons. 
The mechanism that accounts for the increased risk of second trimester loss 
and preterm birth associated with CIN and its treatment is not yet clarified. 
While acquired mechanical weakness of the cervix secondary to surgery might 
seem a logical assumption, more subtle mechanisms may be involved. 
Histological changes in the healed cervix affecting the tensile strength or 
changes in the innate immune system and vaginal microenvironment may also 
be involved. Removing part of the cervix or simply being infected with human 
papillomavirus (HPV) may impair the host’s defence mechanisms, change the 
chemical microenvironment and prevent a pregnancy being maintained to full 
term. Conversely, it may be that women at risk have intrinsic compromised 
defences that promote the persistence of oncogenic HPV infections and the 
development of ascending infections during pregnancy. All these interactions 
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may be best described in the absorbance spectra of the metabolic changes in the 
vagina as described in this study.  
Ascending infection from the vagina into the fetoplacental unit and 
associated inflammation are presumed to be causative in preterm labour. The 
uterus in pregnancy is protected by the cervix via its mucous plug, the local 
synthesis of antimicrobial peptides and proteins and by a ‘benign’ 
Lactobacillus-dominated vaginal microbiota. Lactobacilli spp. inhibits pathogen 
growth by maintaining a hostile pH and secreting species-specific metabolites 
and bacteriocins that limit the growth of other organisms30. By causing scarring 
and a change in the histological structure of the cervix, it is likely that the 
protein expression and metabolites of the cervix are also altered after treatment, 
resulting in an environment, which is more or less hospitable to particular 
bacterial species. It remains unknown whether these changes underlie the 
increased risk of adverse obstetric sequelae, but are a priority area of research. 
FTIR spectroscopy is capable of detecting alterations in the microbiota 
composition31, and thus spectral information should be correlated with 16s 
ribosomal RNA gene sequencing data, as well as proteomic data in future 
prospective studies to facilitate a better understanding of the structural, 
biochemical, metabolic and microbiological changes that result from excisional 
treatment for CIN.  
In conclusion, this study clearly demonstrates that local treatment for cervical 
pre-invasive disease has a direct impact on the biological and biochemical 
processes within the cervix, and this may correlate to the adverse sequelae 
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described in future pregnancies that include preterm birth and premature rupture 
of the membranes, possibly as a results of ascending infections and disruption 
of the immune defence mechanisms. Correlation of the specific biochemical 
markers in the produced spectra with the outcomes of subsequent pregnancies 
in the future may allow the detection of women at high risk of preterm birth and 
enable the selection of women at high risk that would benefit from intensive 
antenatal surveillance when pregnant32. Furthermore, further exploration of the 
mechanistic aspects leading to these changes in the metabolic spectra may 
permit the use of more targeted cause-directed preventative treatment in the 
future. 
Materials and methods 
Study population – Inclusion and Exclusion criteria  
Ethical approval was obtained from the National Research Ethics Service 
Committee London – Fulham (Approval number 13/LO/0126). This study was 
conducted according to the principles of the Declaration of Helsinki and all 
other applicable national or local laws and regulations. All patients gave written 
informed consent before any protocol-specific procedure was performed.  
We included pre-menopausal, non-pregnant women of reproductive age (18-
45 years of age) who attended the colposcopy and were planned to undergo 
local cervical treatment at Imperial College NHS Healthcare Trust.  We 
collected samples before treatment, and a repeat sample 6 months after 
treatment. We also recruited a population of women with normal cytology (+/- 
negative HPV DNA test) attending the colposcopy or general gynaecology 
 Nature Communications 
Page 16 of 46  
 
clinics that would serve as healthy controls. The samples for the healthy group 
were collected at one time point. The recruitment commenced in May 2013 and 
was completed in May 2015.  
Women were included irrespective of their ethnicity, parity, smoking habits, 
phase in their cycle and use of contraception. The type of contraception and the 
time of their cycle (follicular or luteal) were documented. Women who were 
HIV or hepatitis B/C positive, women with autoimmune disorders, and women 
that received antibiotics or pessaries within 14 days of sampling were excluded. 
Detailed medical and gynaecological history was collected for each patient 
including time since last sexual intercourse. Ethnicity was self-reported as 
Caucasian, Asian or Black.  
Patients were anonymized and assigned a unique identifier. For each patient and 
visit, we collected data on the cytology, HPV DNA test and typing and histology, if 
available. The cytology result was classified as normal, borderline or mild dyskaryosis 
(low-grade squamous intraepithelial lesion [LSIL]), moderate or severe dyskaryosis 
(high-grade squamous intraepithelial lesions [HSIL]) and invasive cervical cancer 
(ICC). The histology was defined as normal, CIN1, CIN2, CIN3 or invasive cervical 
cancer.  
Transvaginal ultrasound (Voluson E6 with a 5-9 MHz(RIC5-9-RS series) 
transvaginal probe (GE Healthcare, Zipf, Austria) was used to measure the cervical 
length and volume immediately prior to excision. The dimensions of the cervical cone 
were measured using electronic callipers. The volume was also determined by water 
displacement, using a 50ml syringe. These measurements were taken prior to fixation 
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in formaldehyde, which may result in a degree of sample shrinkage, and thus 
underestimate the size of the excised specimen. These data were used to calculate the 
proportion (percentage) of the length or volume excised. Patients included in the 
analysis of cone depth were categorized according to 1 of 4 categories (untreated 
healthy cervix; treated/cone depth: 1 = <10 mm, 2 = 10-14 mm, 3 = ≥15 mm). Patients 
included in the analysis of percentage excision were categorized according to 1 of 6 
categories (untreated healthy cervix; treated/percentage excision: 1 = 0-10%, 2 = 11-
20%, 3 = 21-30%, 4 = 31-40%, 5 = >40%). 
Sample collection and processing 
A sterile, disposable speculum was inserted, without lubricant, and a cervical sample 
of ThinPrep, liquid-based cytology (LBC) was taken from the cervix (ThinPrep, 
HOLOGIC Inc., Bedford, USA). This was analysed for cytological diagnosis and 
HPV DNA test and typing. HPV DNA test and 16/18 genotyping was carried out 
according to manufacturer’s guidelines using the Abbott RealTime High Risk (HR) 
HPV assay on Abbott M2000 platform; a clinically validated in vitro polymerase 
chain reaction (PCR) assay with identification of HPV-16, -18 or any other of 12 HR 
HPV subtypes (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68)33. From the remaining 
methanol-based fluid, 1 ml was stored at 4° centigrade and was used for 
biospectroscopy analysis at the Centre for Biophotonics, Lancaster University, 
England. Routine high vaginal microbiology swabs were taken and sent for 
microscopy, culture and sensitivity. These swabs were also used to diagnose bacterial 
vaginosis based on the Hay/Ison criteria34. Vaginal pH was measured using CarePlan 
VpH gloves (Inverness Medical, Unipath Ltd., Bedford, UK). 
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Biospectroscopy: slide preparation 
Each sample was agitated to disperse the cell pellet, then a 500µl aliquot 
collected into a clean micro tube. Samples were centrifuged at 2000 rpm for 5 
minutes and the ThinPrep supernatant was aspirated to remove its spectral 
signature (i.e., the methanol fixative). Each sample was then immersed in 500 
µl of distilled H2O, agitated and centrifuged again. The supernatant was 
removed again and the wash step repeated once more. The final pellet was 
immersed in 100 µl of distilled H2O, agitated and dispensed onto IR-reflective 
glass slides (Low-E; Kevley Technologies Inc., Chesterland, OH, USA) and 
allowed to bench dry for a minimum of 24 hours. Samples were then stored in a 
desiccator for a minimum of 48 hours to remove any residual water before 
spectral analysis. For those samples with a resultant poor spectral signal 
considered to be due to fewer cells on the slide, repeat samples were prepared 
using the remaining 500 µl of the original sample and prepared as described 
above. However, the final 100 µl solution was dispensed as 2 x 50 µl aliquots, 
with a 24-hour drying period in between each dispensing, and each aliquot 
being dispensed directly on top of the previous one to achieve a uniform spread 
and thickness of cells. These samples were then desiccated as described above.  
ATR-FTIR spectroscopy, computational and statistical analyses   
Spectral acquisition  
Spectra were acquired using a Tensor 27 FTIR spectrometer with a Helios ATR 
attachment (Bruker Optik GmbH). The instrument was set to take 32 scans at 8 
cm-1 wavenumber spacing with 2 x interferogram zero-filling. Before the 
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spectra were taken, the crystal was cleaned with distilled H2O and inspected by 
video camera to be free of any contaminants. A background spectrum was 
acquired before the sample slide was mounted and stage moved to bring the 
cervical cells in contact with the diamond. Spectra were collected from ten 
random sites on the slide. Spectra were converted to absorbance by Bruker 
OPUS software (Bruker Inc., Billerica, MA, USA). 
Pre-processing and multivariate analysis of spectra 
Each spectrum was classed, cut to the ‘fingerprint region’ (1800-900 cm-1), 
Savitsky Golay differentiated to 1st order and vector normalized. Combining 
vector normalization with differentiation is a typical pre-processing approach35. 
This was followed by Principal Component Analysis coupled to Linear 
Discriminant Analysis (PCA-LDA) cascade using MATLAB R2014a software 
(Mathworks Inc., Natick, MA, USA) together with the toolbox ‘IRootLab’ 
(http://trevisanj.github.io/irootlab/). The number of principal components (nPCS) 
for PCA was calculated to guarantee a ratio of 20 between the number of 
spectra and the number of variables inputted into LDA, to avoid potential 
arbitrary class separation. Typically, the number of PCs was either 9 or 10. The 
PCA-LDA output provided a ‘feature’ for each spectrum for each patient (i.e., 
10 for each patient). An average of these 10 features was taken and used to 
conduct the statistical analyses.  
Peaks found within the ‘biochemical fingerprint’ region contain features 
specific to biomarkers as shown in Supplementary Table 136. Changes in the 
availability of these biomarkers will result in changes in peaks (absorbance), 
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which can reveal patterns of intracellular change. We therefore extracted 7 
wavenumbers associated with biologically important biomarkers for each 
analysis, using means, SD and multiple t tests (corrected for multiple t testing 
using the Holm-Sidak method) to produce a rate of change for each 
wavenumber. These were extracted from pre-processed data (i.e., cut, 1st order 
differentiated, vector normalized) at specified wavelengths within MATLAB.  
Impact of treatment 
Demographic data were summarized using RStudio Version 3.2.1 (RStudio: 
Integrated Development for R. RStudio, Inc., Boston, MA, USA). Differences 
in the patient characteristics between the compared groups were assessed using 
Fishers exact test (GraphPad Prism 6, [GraphPad Software Inc., La Jolla, CA, 
USA]). P-value <0.05 was considered to be statistically significant.  
We assessed the impact that local treatment may have on the cervix by 
comparing the cervical cell spectral absorbance of women with paired samples 
before and after treatment using means, standard deviations (SD) and a 
Student’s t test (Comparison 1). In order to control whether the observed 
differences were a result of the treatment itself or due to the removal of the 
disease (CIN), we performed an additional subgroup analysis to compare 
normal women post-treatment (negative cytology and negative HPV DNA test), 
to untreated normal controls (negative cytology and negative HPV DNA test). 
This was also done using means, SD and a Student’s t test (Comparison 2). We 
further assessed whether the changes in the biochemical fingerprint of the 
cervix correlated to the absolute cone depth (mm) and the proportion 
 Nature Communications 
Page 21 of 46  
 
(percentage) of cervical length excised. We compared the different cone 
depth/proportions groups and also compared these with healthy controls with 
negative cytology irrespective of HPV status by means, SD and one-way 
ANOVA (Comparison 3). All statistical analyses of spectra were conducted 
using GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA, USA).  
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Figure legends 
Figure 1: Flowchart of the included population and different comparison groups.  
Figure 2. PCA-LDA scores plot of ATR-FTIR spectra with regards to LD1: Pre- vs Post-treatment (a) 
together with absorbance per wavenumber (b). The paired samples pre- and post-treatment were significantly 
different along LD1 (Mean/SD (a): 0.004/0.10 for ‘A’; -0.12/0.08 for ‘B’; p<0.0001, 95% CI = -0.17 to -0.08). 
Absorbance associated with lipids, glycomaterials and proteins was shown to have a significant positive rate of 
change for the pre-treatment group compared with the post-treatment group, indicating their higher bioavailability. 
Similarly, absorbance associated amide I and amide II was shown to have a significant positive rate of change for 
the post-treatment group compared within the pre-treatment group. Absorbance associated with glycogen, collagen 
and symmetric phosphate of DNA was shown to have a significant negative rate of change for the pre-treatment 
group compared with the post-treatment group, suggesting lower bioavailability. Similarly, absorbance associated 
asymmetric phosphate for DNA was shown to have a significant negative rate of change for the post-treatment 
group compared with the pre-treatment group (b). ATR-FTIR: Attenuated total reflectance, Fourier-transform 
Infrared; CI: Confidence interval; LD1: Linear Discriminant 1; PCA-LDA: Principal Component Analysis coupled 
to Linear Discriminant Analysis; SD: Standard deviation.  
Figure 3. PCA-LDA scores plot of ATR-FTIR spectra with regards to LD1: controls vs treated (normal 
cytology and HPV –ve); (a) together with absorbance per wavenumber (b). The 2 groups were significantly 
different along LD1 (Mean/SD (a): 0.32/0.10 for Controls; 0.20/0.11 for Treated; p<0.0001, 95% CI = -0.18 to -
0.07). These results evidence that the difference in LD1 was due to the impact of treatment. Absorbance associated 
with amide II was shown to have a significant positive rate of change for the treated group compared with controls, 
indicating higher bioavailability (b). No other significant changes were detected. ATR-FTIR: Attenuated total 
reflectance, Fourier-transform Infrared; CI: Confidence interval; LD1: Linear Discriminant 1; PCA-LDA: Principal 
Component Analysis coupled to Linear Discriminant Analysis; SD: Standard deviation.  
Figure 4. PCA-LDA scores plot of ATR-FTIR spectra with regards to LD1: Healthy Cervix vs Cone Depth 
(a) together with absorbance per wavenumber (b). Mean/SD (a) for each group was: 0.22/0.07 for healthy 
cervix; 0.15/0.07 for <10 mm; 0.19/0.07 for 10-14 mm; 0.13/0.04 for ≥15 mm. A significant difference along LD1 
was detected for healthy cervix vs <10 mm (p=0.0008; 95 CI = 0.03 to 0.12); and for healthy cervix vs ≥15 mm 
(p=0.001; 95 CI = 0.03 to 0.15). No significant difference along LD1 was detected for healthy cervix vs 10-14 mm 
(p=0.13; 95 CI = -0.01 to 0.08). Absorbance associated with amide II was shown to have a significant positive rate 
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of change for <10 mm group compared with healthy cervix, indicating higher bioavailability (b). Similarly, 
absorbance associated with amides I and II were shown to have a significant positive rate of change for ≥15 mm 
compared with healthy cervix, whilst absorbance associated with DNA was shown to have a negative rate of 
change, indicating lower bioavailability. ATR-FTIR: Attenuated total reflectance, Fourier-transform Infrared; CI: 
Confidence interval; LD1: Linear Discriminant 1; PCA-LDA: Principal Component Analysis coupled to Linear 
Discriminant Analysis; SD: Standard deviation.  
Figure 5.  PCA-LDA scores plot of ATR-FTIR spectra with regards to LD1: Healthy Cervix vs Percentage 
Excision (a) together with absorbance per wavenumber (b). Mean/SD (a) for each group was: 0.30/0.07 for 
healthy cervix; 0.16/0.12 for 11-20%; 0.24/0.06 for 21-30%; 0.22/0.09 for 31-40%; 0.21/0.07 for >40%. A 
significant difference along LD1 was detected for healthy cervix vs 11-20% (p=0.002; mean rank difference: 
31.11); for healthy cervix vs 21-30% (p=0.03; mean rank difference: 17.85); for healthy cervix vs 31-40% 
(p=0.007; mean rank difference 23.33; and for healthy cervix vs >40% (p=0.023; mean rank difference: 27.24). 
Absorbance associated with lipids and amide II was shown to have a significant positive rate of change for 11-20% 
compared with healthy cervix, indicating higher bioavailability (b). No other significant differences were detected 
for healthy cervix vs all other groups. ATR-FTIR: Attenuated total reflectance, Fourier-transform Infrared; CI: 
Confidence interval; LD1: Linear Discriminant 1; PCA-LDA: Principal Component Analysis coupled to Linear 
Discriminant Analysis; SD: Standard deviation.  
 
 Nature Communications 
Page 30 of 46  
 
Table 1. Patient characteristics 
 Comparison 1: Treated women with 
paired samples 
 Comparison 2 : Normal post-treatment 
vs. normal untreated controls 
 Comparison 3: Treated by cone 




































Age, years   0.69   0.87   0.50 













Ethnicity, n/N (%)   1.00   0.12   0.24 
Caucasian 22/29 (76) 25/33 (76)  30/39 (77) 11/20 (55)  46/58 (79) 18/27 (67)  
Asian 5/29 (17) 6/33 (18)  6/39 (15) 4/20 (20)  8/58 (14) 4/27 (15)  
Black 2/29 (7) 2/33 (6)  3/39 (8) 5/20 (25)  4/58 (7) 5/27 (18)  
Smoking status, n/N (%)   0.77   0.04*   0.18 
Non-smoker 23/29 (79) 25/33 (76)  27/39 (69) 19/20 (95)  41/58 (71) 23/27 (85)  
Current smoker 6/29 (21) 8/33 (24)  12/39 (31) 1/20 (5)  17/58 (29) 4/27 (15)  
Contraception, n/N (%)   0.98   0.05   0.06 
Nil 11/29 (37) 11/33 (33)  10/39 (25) 13/20 (65)  16/58 (28) 16/27 (59)  
Condoms 1/29 (4) 2/33 (6)  6/39 (15) 2/20 (10)  8/58 (14) 4/27 (15)  
COCP 14/29 (48) 17/33 (52)  20/39 (51) 3/20 (15)  28/58 (48) 4/27 (15)  
POP 2/29 (7) 2/33 (6)  1/39 (3) 1/20 (5)  2/58 (3) 1/27 (4)  
Implant 0/20 (0) 0/33 (0)  0/39 (0) 0/20 (0)  0/58 (0) 1/27 (4)  
Mirena IUS 1/29 (4) 1/33 (3)  1/39 (3) 1/20 (5)  2/58 (3) 1/27 (4)  
Copper IUD 0/29 (0) 0/33 (0)  0/39 (0) 0/20 (0)  1/58 (2) 0/27 (0)  
Vaginal ring 0/29 (0) 0/33 (0)  1/39 (3) 0/20 (0)  1/58 (2) 0/27 (0)  
Parity, n/N (%)   1.00   0.52   0.51 
Nulliparous 21/29 (72) 24/33 (73)  32/39 (82) 15/20 (75)  45/58 (78) 22/27 (81)  
Parous 8/29 (28) 9/33 (27)  7/39 (18) 5/20 (25)  13/58 (22) 5/27 (19)  
Time since last intercourse, 
n/N (%) 
  0.71   0.28   0.31 
>48 hours 26/29 (90) 28/33 (85)  34/39 (87) 15/20 (75)  52/58 (90) 22/27 (81)  
<48 hours 3/29 (10) 5/33 (15)  5/39 (13) 5/20 (25)  6/58 (10) 5/27 (19)  
Phase of menstrual cycle, n/N 
(%) 
  0.40   0.14   0.08 
Luteal 15/29 (52) 18/33 (55)  21/39 (54) 6/20 (30)  29/58 (50) 7/27 (26)  
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 Comparison 1: Treated women with 
paired samples 
 Comparison 2 : Normal post-treatment 
vs. normal untreated controls 
 Comparison 3: Treated by cone 
depth/proportion vs. normal untreated 
controls 
 
Follicular 13/29 (45) 11/33 (33)  14/39 (36) 9/20 (45)  23/58 (40) 14/27 (52)  
Unknown 1/29 (3) 4/33 (12)  4/39 (10) 5/20 (25)  6/58 (10) 6/27 (22)  
Vaginal pH   0.61   0.92   0.37 
<4.5 12/29 (41.5) 13/33 (39)  16/39 (41) 9/20 (45)  24/58 (41) 15/27 (56)  
≥4.5 16/29 (55) 20/33 (61)  21/39 (54) 9/20 (45)  31/58 (53) 10/27 (37)  
Unknown 1/29 (3.5) 0/33 (0)  2/39 (5) 2/20 (10)  3/58 (6) 2/27 (7)  
Bacterial vaginosis, n/N (%)   1.00   0.13   0.16 
No 27/29 (93) 31/33 (94)  35/39 (89) 15/20 (75)  52/58 (89) 21/27 (78)  
Yes 2/29 (7) 2/33 (6)  3/39 (8) 2/20 (10)  5/58 (9) 3/27 (11)  
Unknown 0/29 (0) 0/33 (0)  1/39 (3) 3/20 (15)  1/58 (2) 3/27 (11)  
HPV DNA test, n/N (%)   0.0001*   1.00   0.59 
Negative 1/29 (3) 27/33 (82)  39/39 (100) 20/20 (100)  46/58 (79) 20/27 (74)  
Positive 28/29 (97) 6/33 (18)  0/39 (100) 0/20 (0)  12/58 (21) 7/27 (26)  
 
COCP: Combined oral contraceptive pill; HPV: Human Papillomavirus; HSIL: High-grade intraepithelial lesion; IUD: Intrauterine device; IUS: Intrauterine system; POP: Progesterone-only 
pill; SD: Standard deviation.  
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Supplementary Figure 1. Processing steps for spectra obtained using ATR-FTIR spectroscopy. Step 1: Classifying the data by treatment group; Step 2: Cutting the  
spectra to the fingerprint region (1800-900 cm-1). ATR-FTIR: Attenuated total reflectance, Fourier-transform Infrared.  
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Supplementary Figure 2. Processing steps for spectra obtained using ATR-FTIR spectroscopy. Step 3: 1st order differentiated, followed by vector normalisation; Step 3A: Wavenumber 
extraction using previous data; Step 4: Calculation of percentage variance (i.e., number of Principal Components [PCs] to take forward for PCA-LDA cascade) using the Pareto chart. ATR-
FTIR: Attenuated total reflectance, Fourier-transform Infrared. PCA-LDA: Principal Components Analysis coupled to Linear Discriminant Analysis.
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Supplementary Figure 3. Processing steps for spectra obtained using ATR-FTIR spectroscopy. Step 5: Applying PCA-LDA-Cascade using the previously defined 
number of principal components identified from Pareto plotting. ATR-FTIR: Attenuated total reflectance, Fourier-transform Infrared. PCA-LDA: Principal Components 
Analysis coupled to Linear Discriminant Analysis; LD: Linear Discriminant.  
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Supplementary Figure 3. Processing steps for spectra obtained using ATR-FTIR spectroscopy. Step 5: Applying PCA-LDA-Cascade using the previously defined 
number of principal components identified from Pareto plotting. ATR-FTIR: Attenuated total reflectance, Fourier-transform Infrared. PCA-LDA: Principal Components 
Analysis coupled to Linear Discriminant Analysis; LD: Linear Discriminant.  
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Supplementary Figure 4. PCA-LDA scores plot of ATR-FTIR spectra with regards to LD1: Cone depth (a) together with absorbance per wavenumber (b). Comparison of 
<10 mm with >=15 mm was not significantly different along LD1 (Mean/SD (a): -0.11/0.14 for <10 mm; -0.05/0.16 for >=15 mm; p=0.489, 95% CI = -0.19 to 0.07). Comparison of 
<10 mm with 10-14 mm was significantly different along LD1 (Mean/SD: -0.11/0.14 for <10 mm; -0.24/0.13 for 10-14 mm; p=0.006). Comparison of 10-14 mm with >=15 mm was 
significantly different along LD1 (Mean/SD: -0.24/0.13 for 10-14 mm; -0.05/0.16 for >=15 mm; p=0.002). Absorbance associated lipids were shown to have a significant positive rate 
of change for the 10-14 mm group compared with the >=15 mm group, evidencing their higher bioavailability. No significant differences were detected for wavenumbers associated 
with other biomarkers between all 3 groups (b). ATR-FTIR: Attenuated total reflectance, Fourier-transform Infrared; CI: Confidence interval; SD: Standard deviation.  
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Supplementary Figure 5. PCA-LDA scores plot of ATR-FTIR spectra with regards to LD1: Percentage Excision (a) together with absorbance per wavenumber (b). 
Comparison of 11-20% with 21-30% was not significantly different along LD1 (Mean/SD (a): 0.47/0.07, 0.41/0.08 respectively; p=0.16; 95 CI -0.02 to -0.14). Comparison of 11-20% 
with 31-40% was not significantly different along LD1 (Mean/SD: 0.47/0.07, 0.51/0.07 respectively; p=0.69; -0.12 to 0.05). Comparison of 11-20% with >40% was not significantly 
different along LD1 (Mean/SD: 0.47/0.07, 0.49/0.05 respectively; p=0.98; 95 CI -0.11 to 0.09). Comparison of 21-30% with >40% was not significantly different along LD1 
(Mean/SD: 0.41/0.08; 0.49/0.05 respectively, p=0.10; 95 CI -0.16 to 0.01). Comparison of 31-40% with >40% was not significantly different along LD1 (Mean/SD: 0.51/0.07, 
0.49/0.05 respectively; p=0.92; CI -0.07 to 0.11). A significant difference was detected along LD1 for 21-30% vs 31-40% (Mean/SD: 0.41/0.08, 0.51/0.07, respectively; p=0.0016; 95 
CI -0.16 to -0.03). No significant differences were detected for wavenumbers associated with the 7 biomarkers between all 4 groups (b). ATR-FTIR: Attenuated total reflectance, 
Fourier-transform Infrared; CI: Confidence interval; SD: Standard deviation. 
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Supplementary Table 1.  Important biomarkers 
 
Tentative assignment of Biomarkersa Wavenumber (cm-1) 
Amide I (of proteins predominantly in α helix 
conformation) ~1651 
Amide II (of proteins predominantly in β sheet 
conformation) ~1550 
Methylene chains in lipids ~1470 
Phosphate I - asymmetric (DNA) ~1223 
C-O bands from glycomaterials and proteins ~1170 
Phosphate I - symmetric (DNA) ~1072 
Glycogen & collagen ~1030 
a Movasaghi et al, 200836; N.B.: The signal at a particular wavenumber could have contributions from more than 
one biomarker. Amides I and II are linked to the secondary structure of proteins and are indicative of their 
bioavailability.  
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Percentage Excisionb  
(n=53) 
 
 Category 1:  
<10 mm  
(n=24) 
Category 2:  
10-14 mm  
(n=24) 
Category 3:  
>= 15 mm 
(n=10) 
Category 2:  
11-20% 
(n=9) 
Category 3:  
21-30%  
(n=22) 






Age, years         















Ethnicity, n/N (%)         
   Caucasian 18/27 (67) 19/24 (79) 20/24 (83) 7/10 (70) 5/9 (56) 19/22 (86) 14/14 (93) 6/7 (86) 
   Asian 4/27 (15) 4/24 (17) 3/24 (13) 2/10 (20) 4/9 (44) 2/22 (9) 0/15 (0) 0/7 (0) 
   Black 5/27 (18) 1/24 (4) 1/24 (4) 1/10 (10) 0/9 (0) 1/22 (5) 1/14 (7) 1/7 (14) 
Smoking status, n/N (%)         
   Non-smoker 23/27 (85) 19/24 (79) 15/24 (63) 7/10 (70) 7/9 (78) 17/22 (77) 8/15 (53) 5/7 (71) 
   Current smoker 4/27 (15) 5/24 (21) 9/24 (37) 3/10 (30) 2/9 (22) 5/22 (23) 7/15 (47) 2/7 (29) 
Contraception, n/N (%)         
   Nil 16/27 (59) 6/24 (25) 8/24 (33.5) 2/10 (20) 3/9 (33) 7/22 (32) 4/15 (26) 0/7 (0) 
   Condoms 4/27 (15) 4/24 (17) 2/24 (8.5) 2/10 (20) 1/9 (11) 2/22 (9) 3/15 (20) 2/7 (29) 
   COCP 4/27 (15) 12/24 (50) 12/24 (50) 4/10 (40) 5/9 (56) 12/22 (54) 6/15 (40) 4/7 (57) 
   POP 1/27 (4) 1/24 (4) 0/24 (0) 1/10 (10) 0/9 (0) 0/22 (0) 1/15 (7) 0/7 (0) 
   Implant 1/27 (4) 0/24 (0) 0/24 (0) 0/10 (0) 0/9 (0) 0/22 (0) 0/15 (0) 0/7 (0) 
   Mirena IUS 1/27 (4) 1/24 (4) 1/24 (4) 0/10 (0) 0/9 (0) 1/22 (5) 0/15 (0) 0/7 (0) 
   Copper IUD 0/27 (0) 0/24 (0) 0/24 (0) 1/10 (10) 0/9 (0) 0/22 (0) 0/15 (0) 1/7 (14) 
   Vaginal ring 0/27 (0) 0/24 (0) 1/24 (4) 0/10 (0) 0/9 (0) 0/22 (0) 1/15 (7) 0/7 (0) 
Parity, n/N (%)         
   Nulliparous 22/27 (81) 19/24 (79) 20/24 (83) 6/10 (60) 8/9 (89) 18/22 (82) 12/15 (80) 5/7 (71) 
   Parous 5/27 (19) 5/24 (21) 4/24 (17) 4/10 (40) 1/9 (11) 4/22 (18) 3/15 (20) 2/7 (29) 
Time since last intercourse, n/N (%)         
   >48 hours 22/27 (81) 19/24 (79) 24/24 (100) 9/10 (90) 6/9 (67) 21/22 (95) 15/15 (100) 7/7 (100) 
   <48 hours 5/27 (19) 5/24 (21) 0/24 (0) 1/10 (10) 3/9 (33) 1/22 (5) 0/15 (0) 0/7 (0) 
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Percentage Excisionb  
(n=53) 
Phase of menstrual cycle, n/N (%)         
   Luteal 7/27 (26) 14/24 (58) 9/24 (38) 6/10 (60) 6/9 (67) 12/22 (55) 6/15 (40) 3/7 (43) 
   Follicular 14/27 (52) 8/24 (34) 12/12 (50) 3/10 (30) 3/9 (33) 10/22 (45) 6/15 (40) 3/7 (43) 
   Unknown 6/27 (22) 2/24 (8) 3/24 (12) 1/10 (10) 0/9 (0) 0/22 (0) 3/15 (20) 1/7 (14) 
Vaginal pH         
   <4.5 15/27 (56) 12/24 (50) 9/24 (38) 3/10 (30) 4/9 (44) 9/22 (41) 8/15 (53) 2/7 (29) 
   >=4.5 10/27 (37) 11/24 (46) 14/24 (58) 6/10 (60) 5/9 (56) 12/22 (55) 6/15 (40) 4/7 (57) 
   Unknown/NA 2/27 (7) 1/24 (4) 1/24 (4) 1/10 (10) 0/9 (0) 1/22 (4) 1/15 (7) 1/7 (14) 
Bacterial vaginosis, n/N (%)         
   No 21/27 (78) 22/24 (92) 22/24 (92) 8/10 (80) 8/9 (89) 22/22 (100) 14/15 (94) 5/7 (71) 
   Yes 3/27 (11) 2/24 (8) 1/24 (4) 2/10 (20) 1/9 (11) 0/22 (0) 0/15 (0) 2/7 (29) 
   Unknown 3/27 (11) 0/24 (0) 1/24 (4) 0/10 (0) 0/9 (0) 0/22 (0) 1/15 (6) 0/7 (0) 
Follow up cytology/HPV, n/N (%)         
   Normal & HPV -ve NA 14/24 (58) 19/24 (79) 6/10 (60) 8/9 (89) 10/22 (45) 14/15 (93) 4/7 (58) 
   Normal & HPV +ve NA 4/24 (17) 4/24 (17) 1/10 (10) 1/9 (11) 7/22 (32) 0/15 (0) 1/7 (14) 
   LSIL & HPV –ve NA 3/24 (13) 1/24 (4) 2/10 (20) 0/9 (0) 3/22 (13) 1/15 (7) 1/7 (14) 
   LSIL & HPV +ve NA 1/24 (4) 0/24 (0) 1/10 (10) 0/9 (0) 1/22 (5) 0/15 (0) 1/7 (14) 
   HSIL & HPV -ve NA 1/24 (4) 0/24 (0) 0/10 (0) 0/9 (0) 1/22 (5) 0/15 (0) 0/7 (0) 
   HSIL & HPV +ve NA 1/24 (4) 0/24 (0) 0/10 (0) 0/9 (0) 0/22 (0) 0/15 (0) 0/7 (0) 
HPV DNA test, n/N (%)         
   Negative 20/27 (74) 18/24 (75) 20/24 (83) 8/10 (80) 8/9 (89) 14/22 (64) 15/15 (100) 5/7 (72) 
   Positive 7/27 (26) 6/24 (25) 4/24 (17) 2/10 (20) 1/9 (11) 8/22 (36) 0/15 (0) 2/7 (28) 
a Patients were included in the dimensional analyses if they had had treatment and had follow up data at 6 months after treatment. b There was insufficient patients in Category 1 to include in 
the analysis. No segregation was made based on histology, cytology or HPV testing. COCP: Combined oral contraceptive pill: IUD: Intrauterine device; IUS: Intrauterine system; NA: Not 







3 Project Two  
This paper has been accepted for publication by Scientific Reports as: 
“Imaging cervical cytology with scanning near-field microscopy 
(SNOM) coupled with an IR-FEL”  
Diane E. Halliwell, Camilo L. M. Morais,  Kássio M. G. Lima, Julio Trevisan, Michele 
R. F. Siggel-King, Tim Craig, James Ingham, David S. Martin, Kelly Heys, Maria 
Kyrgiou, Anita Mitra, Evangelos Paraskevaidis, Georgios Theophilou,  Pierre L. 




I collaborated with the co-authors on this project by preparing the samples for 
imaging; acting as biological consultant during experimental shifts; acting as Second 
Commissioner during experimental shifts at the ALICE facility at Daresbury during 
2015; and helping to prepare the manuscript for publication. This work was performed 
under the supervision of Professor Francis L. Martin.  
…………………………………  ………………………………………… 
Diane E. Halliwell     Professor Francis L. Martin 
 
 Scientific Reports 
 
 
Dear Prof Martin,  
 
We are delighted to accept your manuscript entitled "Imaging cervical cytology with scanning near-
field optical microscopy (SNOM) coupled with an IR-FEL" for publication in Scientific Reports. Thank 
you for choosing to publish your work with us.  
 
You should have just received another email from scientificreports@nature.com with instructions for 
the next step, which is to complete your publication agreements. To continue with your publication 
agreements you will need to create a new account on this new system. Please complete these as soon as 
possible so we can start preparing your manuscript for publication. The agreements include the licence, 
which defines the terms of publication, and billing information for your Open Access article.  
 
After we've prepared your paper for publication, you will receive a PDF proof for checking. At that 
point, please check the author list and affiliations to ensure that they are correct. For the main text, only 
errors that have been introduced during the production process or those that directly compromise the 
scientific integrity of the paper may be corrected at this stage. Please ensure that only one author 
communicates with us and that only one set of corrections is returned. The corresponding (or 
nominated) author is responsible on behalf of all co-authors for the accuracy of all content, including 
spelling of names and current affiliations.  
 
To ensure prompt publication, your proofs should be returned within two working days; please let us 
know immediately if there is any period within the next two weeks in which you (or the nominated 
author) won't be available.  
 
Acceptance of your manuscript is conditional on all authors' agreement with our publication policies 
(seehttp://www.nature.com/srep/policies/index.html). In particular, your manuscript must not be 
published elsewhere and there must be no announcement of this work to any media outlet until the 
publication date is confirmed. We will inform you by email as soon as your manuscript is scheduled for 
publication, which will be after we have received and approved your proof corrections. Advice about 
media relations is available from NPG's press office at press@nature.com.  
 
Your article will be open for online commenting on the Scientific Reports website. You may use the 
report facility if you see any comments which you consider inappropriate, and of course, you can 
contribute to discussions yourself. If you wish to track comments on your article, please register for this 
service by visiting the 'Comments' section in the full text (HTML) version of your paper.  
 
**A form to order reprints of your article is available at http://www.nature.com/reprints/author-
reprints.html. To obtain the special author reprint rate, orders must be made within a month of the 
publication date. After that, reprints are charged at the normal (commercial) rate.**  
 
We look forward to publishing your article.  
 
Best regards,  
 
Christian Eggeling  
Editorial Board Member  
Scientific Reports 
 Scientific Reports 
Page 1 of 48 
 
Imaging cervical cytology with scanning near-field optical microscopy (SNOM) coupled 
with an IR-FEL   
Diane E. Halliwell,a Camilo L. M. Morais,b Kássio M. G. Lima,b Julio Trevisan,c Michele R. F. 
Siggel-King,de Tim Craig,d James Ingham,d David S. Martin,d Kelly Heys,a Maria Kyrgiou,f,g 
Anita Mitra,f,g Evangelos Paraskevaidis,h Georgios Theophilou,i Pierre L. Martin-Hirsch,aj 
Antonio Cricenti,k Marco Luce,k Peter Weightman,d and *Francis L. Martina 
 
a Centre for Biophotonics, LEC, Lancaster University, Lancaster, UK; b Biological Chemistry 
and Chemometrics, Institute of Chemistry, Federal University of Rio Grande do Norte, Natal 
59072-970, RN, Brazil; c Institute of Astronomy, Geophysics and Atmospheric Sciences 
University of São Paulo, Brazil; d Department of Physics, University of Liverpool, Oliver 
Lodge Building, Liverpool, UK; e Accelerator Science and Technology Centre (ASTEC), 
STFC Daresbury Laboratory, UK; f Institute of Reproductive and Developmental Biology, 
Department of Surgery & Cancer, Faculty of Medicine, Imperial College, London, UK; g West 
London Gynaecological Cancer Centre, Imperial College NHS Healthcare, London, UK; h 
Department of Obstetrics and Gynaecology, University of Ioannina, Ioannina, Greece; i St 
James Hospital, Leeds, West Yorkshire, UK; j Department of Obstetrics and Gynaecology, 
Lancashire Teaching Hospitals NHS Trust Foundation, Preston, UK. k Istituto di Struttura 
della Materia, CNR, via del Fosso del Cavaliere 100, Rome, Italy.  
*Correspondence and request for materials should be addressed to Professor Martin, Centre 
for Biophotonics, LEC, Lancaster University, Lancaster LA1 4YQ, UK; Email: 
f.martin@lancaster.ac.uk; Tel: +44(0)1524 51020.  
Scientific Reports 
Page 2 of 48 
 
Abstract 
Cervical cancer remains a major cause of morbidity and mortality among women, especially 
in the developing world. Increased synthesis of proteins, lipids and nucleic acids is a condition 
for the rapid proliferation of cancer cells. We show that scanning near-field optical 
microscopy in combination with an infrared  free electron laser (SNOM-IR-FEL), is able to 
distinguish between normal and squamous low-grade and high-grade dyskaryosis, and 
between normal and mixed squamous/glandular pre-invasive and adenocarcinoma cervical 
lesions, at designated wavelengths associated with DNA, amides I and II and lipids. These 
findings evidence the promise of the SNOM-IR-FEL technique in obtaining chemical 
information relevant to the detection of cervical cell abnormalities and cancer diagnosis at 
spatial resolutions below the diffraction limit (≥0.2 µm). We compare these results with 
analyses following attenuated total reflectance Fourier-transform infrared (ATR-FTIR) 
spectroscopy; although this latter approach has been demonstrated to detect underlying 
cervical atypia missed by conventional cytology, it is limited by a spatial resolution of ~3 µm 
to 30 µm.  
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Cervical cancer is associated with the persistent infection of high-risk types of Human 
papillomavirus (HPV), together with other socioeconomic co-factors1. Screening involves 
cytological and histological classification of cervical cells. In the UK, cytological examination 
of cervical squamous cells is classified as normal, borderline or mild dyskaryosis, moderate or 
severe dyskaryosis and invasive cervical cancer (ICC). Histology is defined as normal, 
cervical intra-epithelial neoplasia (CIN): CIN1, CIN2, CIN3, or invasive cervical cancer.  For 
atypical cells found in the glandular cells of the cervix, the pre-invasive lesion of 
adenocarcinoma is defined by changes termed cervical glandular intraepithelial neoplasia 
(CGIN), and sub-classified as low-grade cervical intra-epithelial glandular neoplasia 
(LGCGIN) and high-grade cervical intra-epithelial glandular neoplasia (HGCGIN). Squamous 
and glandular lesions may co-exist together and are defined by the level of CIN together with 
either LGCGIN or HGCGIN. Conventional screening is flawed as it is dependent on the 
subjective visual inspection of cytology; this often results in mis-diagnoses when grading 
samples2.   
Attenuated total reflectance, Fourier-transform infrared (ATR-FTIR) spectroscopy has 
shown potential over conventional screening methods, demonstrating it can segregate grades 
of cervical cytology more accurately than conventional cytological screening3,4, classify 
cervical cytology based on HPV infection with low- or high-risk types5, and can diagnose 
underlying disease more accurately that conventional cytology screening2. However, FTIR 
spectroscopy is limited in spatial resolution by the effect of diffraction, defined as the 
interference of waves when they hit an obstacle or slit. This effect restricts the spatial 
resolution of FTIR to about half the wavelength of light or ~3 µm to 30 µm6, with the 
resolution being a measure of how closely the lines of an image can be resolved (i.e., the 
number of independent pixels per value per unit length).  
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Scanning near field optical microscopy (SNOM) belongs to a family of nanoscopic 
techniques that have shown potential in providing detailed information on cell topography and 
cytoplasmic structures.  
SNOM has a clear advantage over conventional infrared IR microscopy in terms of spatial 
resolution because it is able to overcome the diffraction limit; this is achieved by the use of an 
apertured fibre optic scanning tip. The SNOM technique requires relatively high photon 
intensities such as those provided by an IR free electron laser (IR-FEL). The SNOM-IR-FEL 
enables the simultaneous collection of topography and optical features at scales not normally 
achieved with conventional IR techniques to produce high quality, chemically-rich images at 
designated wavelengths with a spatial resolution of ≥0.2 µm7,8.   
Increased synthesis of proteins, lipids and nucleic acids is a condition for the rapid 
proliferation of cancer cells9, and changes in the bioavailability of these biomarkers can reveal 
important patterns of intracellular change. The IR-FEL on the ALICE accelerator at 
Daresbury Laboratory (Warrington, UK) is tuneable over the range of 5.5 µm to 8.8 µm 
(~1818 cm-1 to ~1136 cm-1), which includes a number of biologically important biomarkers10 
at designated wavenumbers or wavelengths (Table 1). These biomarkers have previously been 
used to separate normal, low- and high-grade dyskaryosis and cancer cells from each other2. 
SNOM has been used to investigate the localisation of molecules within cell membranes of 
prostate cancer cells11. Further research demonstrated SNOM can accurately define both the 
cell surface and internal structures in both healthy and anomalous sperm, including the 
acrosome, nucleus and the organisation of mitochondria12, and has demonstrated potential for 
single molecule imaging13. The application of SNOM to oesophageal cancer tissue studies 
provided evidence of its potentiality for cancer diagnosis8. The increased spatial resolution of 
SNOM has the potential to reveal and quantify highly localised cancer-related changes in 
cervical cells at the sub-cellular level (1-0.1 µm), and more accurately and precisely than 
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conventional IR techniques. The above described IR-SNOM studies were all carried out in 
reflection mode. To be best of our knowledge this is the first publication reporting data 
obtained using IR-SNOM in transmission mode, and using IR-SNOM to image whole cervical 
cells. 
The aim of this pilot study was to assess the potential of SNOM in combination with an 
IR-FEL in the detection of the biophysical properties of cervical cell abnormalities. Spectra 
were also collected using traditional ATR-FTIR biospectroscopy to investigate the differences 
between techniques. 
Results 
We recruited 5 patients into this pilot study; the youngest aged 25 years (squamous & 
glandular pre-invasive lesions [CIN2, HGCGIN]) and the oldest 42 years (squamous lesion; 
low-grade dyskaryosis). Table 2 shows the characteristics for each patient; limited 
demography was available for the patient diagnosed with high-grade dyskaryosis.  
Two out of the 5 patients were current smokers (high-grade dyskaryosis and CIN2 
HGCGIN), and 1 patient was taking antibiotics (CIN2, HGCGIN). Four patients tested 
positive for HPV; none for HPV 18 and 2 for HPV 16. Both normal and high-grade 
dyskaryosis tested positive for HPV ‘other’ type (i.e., not high-risk HPV types 16 or 18); only 
normal had an abnormal high vaginal swab. All patients were tested for bacterial vaginosis 
and were normal.  
A total of 34 cells were included in the SNOM images. The number of cells was evenly 
distributed for low-grade dyskaryosis, CIN2, HGCGIN and adenocarcinoma stage 1B1 (6, 5, 
and 5 cells each, respectively). Sixteen cells were imaged for normal and 2 for high-grade 
dyskaryosis, which was limited by the number of acceptable cells on the slide. Each SNOM 
scan comprised topographic, raw transmission (SNOM light) and IR (light) intensity reference 
images all collected simultaneously at a fixed wavelength. Example SNOM-IR-FEL 
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topography and associated transmission images for the pre-invasive lesion (CIN2, HGCGIN) 
is presented in Figure 6 (Methods; computational analysis). The topography and associated 
transmission images for the other 4 cells types is presented in Supplementary Figs: 1-4.  
Changes in biomarkers at different grades of cervical dyskaryosis detected by 
SNOM-IR-FEL. When applied to spectra, Principal Component Analysis (PCA) identifies 
common sources of variance across spectra and collates them into a small number of 
dimensions (i.e., Principal Components [PCs]). Similar behaviour between samples ‘nests’ 
them closer together. PC score plots (Figure. 1) showed adequate separation for amide I 
between normal, high-grade dyskaryosis and CIN2, HGCGIN, with PC1 representing 84.19% 
and PC2 8.22% of the data variance (Figure. 1 [a]). The overlap observed for low-grade 
dyskaryosis and adenocarcinoma Stage 1B1 in the amide I band indicates there was 
insufficient information to achieve complete class segregation. Clean separation was observed 
for amide II between all samples, with the exception of normal and high-grade dyskaryosis, 
with PC1 and PC2 signifying 74.99% and 17.41%, respectively of the data variation (Figure. 
1 [b]). There was considerable overlap for lipids for low- and high-grade dyskaryosis and 
adenocarcinoma Stage 1B1, with good separation observed between normal and CIN2, 
HGCGIN; PC1 was 76.39%, and PC2 was 16.75% (Figure. 1 [c]). All five cell types were 
distinguishable for DNA, although low- and high-grade dyskaryosis were very close to each 
other, with PC1 representing 84.28% and PC2 7.81% of the data variance (Figure. 1 [d]). 
Hotelling T2 versus Q Residuals were plotted to assess how well the model described the 
samples with the optimal score for Hotelling T2 being 100%, and the optimum score for Q 
Residuals being 0%. These plots show that all the samples fell with the 95% confidence limits 
and that no outliers were detected (Supplementary Fig.5). Validation of the PCA model was 
performed using Q Residuals to measure variation outside the PCA model for each sample 
according each biomarker response (Supplementary Fig. 6); and Hotelling T2 was used to 
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measure variation within the PCA model for each sample according each biomarker response 
(Supplementary Fig. 7). All values fell within the 95% confidence limit and show there were 
no outliers.  The T2 and Q residuals plots show the data fits the model well.  
The area of absorbance for each biomarker for each cell type is shown in Figure 2, with the 
percentage of area variation compared with normal shown in Table 3. For low-grade 
dyskaryosis, amide I and lipids were lower than normal cells (-73% and -31%, respectively) 
with large increases detected for amide II and DNA (143% and 111%, respectively). This 
pattern of decreased amide I and lipids was also observed for high-grade dyskaryosis (amide I: 
-94%, lipids: -78%), and similarly, amide II and DNA were higher (40% and 132%, 
respectively). All four biomarkers were higher for the pre-invasive squamous/glandular cells 
(CIN2, HGCGIN) than normal cells, with dramatic increases observed for amide II (509%) 
and DNA (1272%). Amide I was 38% higher and lipids were 93% higher. Conversely, the 
profile for adenocarcinoma Stage 1B1 was similar to low-grade dyskaryosis for amide I (-
66%) and lipids (-47%).  Adenocarcinoma Stage 1B1 was the only cell type in which a 
decrease in amide II was detected (-46%), and DNA availability was approximately half that 
detected for CIN2, HGCGIN (585%).  
Spectra collected by ATR-FTIR spectroscopy for each cell type were very similar to each 
other, where the signal’s difference appeared to be close to the instrument noise 
(Supplementary Fig. 8). However, the application of PCA was able to discriminate each cell 
type by class (Supplementary Fig. 9). PCA alone is often not enough to segregate out data 
classes or clusters sufficiently. By applying a supervised technique such as Linear 
Discriminant Analysis (LDA) to the PCA output as above (PCA-LDA), it promotes inter-class 
variation to be identified whilst preventing over-fitting of the data. PCA-LDA revealed good 
separation of classes, although 2 spectra from the normal set appeared within the CIN2, 
HGCGIN class (Figure 3).  
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Successive Projections Algorithm (SPA) is a variable selection technique that can produce 
models with good prediction ability. Used together with LDA (SPA-LDA), this technique 
produced similar results to PCA-LDA, although the clustering of cell types was more acute 
(Figure. 4), with discriminant wavenumbers being 1022, 1157, 1184, 1234, 1331, 1512, 1566, 
1662, 2345 and 2939 cm-1, and 8 of these occupying the fingerprint region (1800-900 cm-1); 
(Figure 5).  The tentative assignment of these wavenumbers in the fingerprint region to 
associated biomarkers is given in Table 4.  
Discussion 
Although the number of cells per patient per cell type is small, the results evidence the 
promise of the SNOM-IR-FEL technique in obtaining chemical information relevant to the 
detection of cervical cell abnormalities and cancer diagnosis at high spatial resolution. Clear 
trends in increased bioavailability of DNA were seen across all four disease cell types 
comparative to normal, with dramatic increases observed for the pre-invasive lesion of 
squamous/glandular neoplasia and for adenocarcinoma Stage 1B1. Both of these patients were 
infected with HPV 16, which is known to integrate into the host’s DNA and produce a range 
of proteins that accelerate biochemical cascades that result in an overexpression of proto-
oncogenes, stimulate rapid cell growth and increase the expression of proteins necessary for 
DNA replication14,15. It is possible that the increased DNA expressed in these cell types may 
be a combination of increased human and viral DNA. The dramatic increase in all biomarkers 
for the pre-invasive squamous/glandular lesion suggests a ‘commitment’ to carcinogenesis, 
whilst the mechanism behind the downregulation in proteins and lipids in adenocarcinoma is 
unclear, and may reflect the tumour achieving some form of steady-state, or that energy 
supply is exhausted. It should also be noted that ‘normal’ cells were infected with HPV 
‘other’ type (i.e., not high-risk HPV type 16 or 18), and this patient had an abnormal high 
vaginal swab which may have influenced the profile observed here.  
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For the squamous lesions (low- and high-grade dyskaryosis), the results suggests the 
production of lipids and specific proteins featuring amide I bonding has been down-regulated.  
An amide bond is formed when two amino acids are joined at the C=O and N-H junction. 
Amide I is associated with the stretching of C=O bonds in polypeptides, whilst amide II is 
associated with the bending of the N-H bond. Previous vibrational work has established 
correlations between the frequencies of amides I/II to the secondary structure of polypeptides, 
which include α helices, β sheets, turns and undefined structure16. The increases in amide II 
for low-grade and high-grade dyskaryosis and the pre-invasive squamous/glandular lesion 
may be due to the increased production of specific polypeptides that feature amide II bonding 
in their secondary structures, and may represent a singular biomarker of importance. Previous 
work has shown the presence of proteins in the β sheet conformation has been linked in 
formation of the protein aggregates and fibrils observed in many human diseases, notably the 
amyloids seen in Alzheimer's disease17. 
Whilst lipids are associated with the proliferation of cancer cells9, we detected increases 
only for the mixed pre-invasive squamous/glandular lesion. However, it should be noted that 
the wavelength for lipids at 5.71 µm lies near the limit of the IR-FEL where the beam 
intensity was low and shot-to-shot stability less good than for other wavelengths, which 
resulted in SNOM transmission images that had a lower signal-to-noise ratio. Overall, 
although the SNOM-IR-FEL technique was able to distinguish different cell types according 
to biomarkers, the delineation was less distinctive between low- and high-grade dyskaryosis 
than for normal, pre-invasive squamous/glandular lesion and adenocarcinoma Stage 1B1, 
which may be influenced by the small number of cells imaged. Given that the underlying 
normal cellular activity of squamous cells is different to mucus-producing glandular cells, it is 
not unreasonable to assume that the biological processes involved in the development of 
squamous cervical lesions may be different to glandular lesions.  
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As expected, spectra collected the traditional way using ATR-FTIR coupled with 
multivariate analysis, was able to segregate the cell types clearly into classes. Spectra for the 
normal sample were collected the day before those collected for the pre-invasive 
squamous/glandular sample; thus the appearance of two spectra within the pre-invasive class 
is likely due to natural variation of the normal sample rather than cross-contamination. The 
range of biomarkers available for investigation with ATR-FTIR was broader than that 
available for the SNOM-IR-FEL measurements in this experiment and encompasses the whole 
of the fingerprint region. Nonetheless, a large portion of this region was still available for 
investigation with SNOM-IR-FEL, where the wavelength range is dictated by the ALICE 
accelerator beam energy and FEL undulator gap settings. 
Although SNOM has been shown to reveal cytoplasmic structures in previous studies12, the 
SNOM-IR-FEL images obtained in this study were difficult to interpret in terms of structures. 
This was due to the use of a cleaved fibre for the SNOM imaging, which added significant tip 
artefacts to the topographical image and often off-set the topographic from the transmission 
images. Additionally, the method used to prepare the slides (cytospinning) resulted in many 
cells rupturing upon impact with the BaF2 slide and left very few whole cells that were free of 
debris. However, care was taken to avoid any debris within the field of images as much as 
possible, and to ensure that all images contained the whole cells.  
In terms of a diagnostic tool for use in routine patient screening, the technique of ATR-
FTIR has low running costs and inexpensive consumables, together with a turnaround of 15-
20 minutes per sample. The SNOM-IR-FEL technique has higher running (estimated at 
£250/hour) and consumables costs, and requires specialised fibre optics that need to be 
replaced regularly. In this experiment, the time required to collect each SNOM scan, at each 
wavelength, was approximately 80-100 minutes, depending upon the number of pixels 
obtained per image. Although building small accelerators on hospital sites is achievable, their 
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installation would require specialised personnel and a safe location away from the main 
hospital thoroughfare. Therefore, between the two techniques studied here, ATR-FTIR 
spectroscopy is the technique of choice for routine screening applications.   
The results presented here demonstrate that the SNOM-IR-FEL technique is able to 
correctly identify cervical cell abnormalities using whole cells. In this study, the SNOM 
technique was used in ‘low resolution’ mode, which enabled direct comparison with the ATR-
FTIR method. SNOM has a clear advantage over ATR-FTIR in terms of being a ‘precision 
tool’ that can be used to identify the location of biomarkers within the cell, leading to further 
understanding of how cancer develops and in identifying targets of therapeutic potential. It 
can be tuned to specific wavenumbers/wavelengths, which may help to exclude the ‘noise’ of 
other biomarkers that lie within close proximity, and makes the extraction of specific 
biomarkers more accessible.  
Methods  
Study population 
Ethical approval was obtained from the National Research Ethics Service Committee London 
– Fulham (Approval number 13/LO/0126). This study was conducted according to the 
principles of the Declaration of Helsinki and all other applicable national or local laws and 
regulations. All patients gave written informed consent before any protocol-specific procedure 
was performed.  
Patients were selected from a larger cohort of patients taking part in a larger study and 
were chosen based on their cytology and histology typing (worse grade) to match a diagnosis 
of ‘normal’, squamous lesions (low-grade dyskaryosis and high-grade dyskaryosis), pre-
invasive mixed lesions involving both squamous and glandular cells (CIN2, HGCGIN), or 
developed glandular lesions (adenocarcinoma). We selected pre-menopausal, non-pregnant 
women of reproductive age (18-45 years of age) who were scheduled, if necessary, to undergo 
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local cervical treatment at Imperial College NHS Healthcare Trust. All samples were collected 
prior to treatment. The recruitment commenced in May 2013 and was completed in May 
2015. 
Patients were anonymised and assigned a unique identifier. We collected patient 
characteristics that included ethnicity, parity, smoking habits, antibiotic use within the last 2 
weeks, phase in their cycle and use of contraception. The type of contraception and the time of 
their cycle (follicular or luteal) were documented. Medical and gynaecological history was 
collected for each patient including time since last sexual intercourse. For each patient, we 
collected data on the cytology, HPV DNA test and typing and histology, if available. Ethnicity 
was self-reported as Caucasian, Asian or Black. 
Women who were HIV or hepatitis B/C positive, women with autoimmune disorders, and 
women that received pessaries within 14 days of sampling were excluded. Women with a 
previous history of cervical treatment were also excluded. 
Sample collection  
A sterile, disposable speculum was inserted, without lubricant, and a cervical sample of 
ThinPrep, liquid-based cytology (LBC) was taken from the cervix (ThinPrep, HOLOGIC Inc., 
Bedford, USA). This was analysed for cytological diagnosis and HPV DNA test and typing. 
HPV DNA test and 16/18 genotyping was carried out according to manufacturer’s guidelines 
using the Abbott RealTime High Risk (HR) HPV assay on Abbott M2000 platform; a 
clinically validated in vitro polymerase chain reaction (PCR) assay with identification of 
HPV-16, -18 and 12 other HR HPV subtypes (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68)18. 
From the remaining methanol-based fluid, 1 ml was stored at 4° centigrade at the Centre for 
Biophotonics, Lancaster University, England, until preparation for SNOM-IR-FEL and ATR-
FTIR analysis.  
Slide preparation  
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Each sample was agitated to disperse the cell pellet, and then a 500 µl aliquot was collected 
from the 1 ml sample into a clean micro tube. The 500 µl aliquots were centrifuged at 2000 
rpm for 5 minutes and the ThinPrep supernatant was aspirated from above the pellet to 
remove its spectral signature (i.e., the methanol fixative). Each sample was re-suspended in 
500 µl of distilled H2O, agitated and centrifuged again. The supernatant was removed again 
and the wash step was repeated once more. For ATR-FTIR analysis, the final pellet was 
immersed in 100 µl of distilled H2O, agitated and dispensed onto IR-reflective glass slides 
(Low-E; Kevley Technologies Inc., Chesterland, OH, USA) in a uniform spread of whole 
cells and allowed to bench dry for a minimum of 24 hours. Samples were then stored in a 
desiccator for a minimum of 48 hours to remove any residual water before spectral analysis. 
For SNOM-IR-FEL analysis, the remaining 500 µl aliquot was washed as described above. 
If the final pellet was small, it was suspended in 500 µl of distilled H2O, and larger pellets in 
1000 µl of distilled H2O. Each suspension was then agitated to disperse the pellet, and 5-6 
drops added to a cytofunnel held in a cytoclip that had been pre-loaded with a barium fluoride 
(BaF2)  slide; (Crystan Ltd, Dorset, UK). Samples were spun at 3000 rpm for 5 minutes in a 
Cytospin™ 4 Cytocentrifuge (Thermo Fisher Scientific Inc., MA, USA) to disperse the cells 
in a single layer onto the slide. Slides were then housed in slide cartridges and kept in a 
desiccator until required.    
SNOM and IR-FEL experimental set-up 
The experiments were performed on the IR-FEL beamline at the ALICE energy recovery 
linear accelerator at Daresbury Laboratory19, 20. The wavelength of light from the FEL was 
selected by changing the undulator gap and, at the present accelerator settings, could be varied 
continuously from about 5.5 µm to 8.8 µm (~1818 cm-1 to ~1136 cm-1), a range which covers 
a number of biologically important absorption bands. The IR-FEL operates at a macro-pulse 
repetition rate of 10 Hz, which limits, and determines, the rate of data collection. The IR light 
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from the FEL was transported to the experimental area via an evacuated beamline and exited 
the beamline through a KBr window. The intensity of the FEL radiation was attenuated using 
a set of polarisers and focussed onto the sample. A CaF2 beam-splitter enables the FEL 
radiation to be split so that approximately 80% went to the SNOM and 20% was used as a 
reference signal. The reference signal was monitored with a single-element pyro detector. 
The general principal of operation for the SNOM used in these experiments has been 
previously described7. In brief, the scanning tip is a specially prepared infrared-transmitting 
Chalcogenide glass fibre, where one end is etched to a sharp tip. Gold is then evaporated onto 
the tip so that it covers all but the very end, forming an aperture of 0.1-1 µm in diameter 
through which the light is collected. The fibre tip is then rastered over the surface of the 
sample, keeping the tip-to-sample distance constant with shear-force feedback. A single IR-
FEL macro-pulse is used for each pixel of the images. The standard mode of operation for IR-
SNOM is reflection, where the light approaches the sample at a grazing incidence angle of 
approximately 15° and the reflected light is collected by the fibre, transmitted through the 
fibre and detected using a liquid nitrogen cooled mercury-cadmium-telluride (MCT) detector.  
Here we report the first measurements made in transmission mode, where the sample was 
illuminated through the slide; the light that was transmitted through the sample was collected 
by the fibre. For the measurements reported here, the fibre was cleaved and the entire 6-mm  
diameter fibre core was used to collect the infrared light signal so that a direct comparison 
could be made with standard IR techniques such as ATR-FTIR. The SNOM was incorporated 
into an inverted optical microscope, which was used to locate specific cells of interest on the 
sample and to position them within the SNOM scan area. 
A BaF2 slide containing the cells was mounted onto the SNOM and scans acquired at fixed 
wavelengths of 5.71 µm/~1750 cm-1 (lipids), 6.06 µm/~1650 cm-1 (amide I), 6.46 µm/~1550 
cm-1 (amide II) and 8.16 µm/~1225 cm-1 (DNA-asymmetric phosphate) for each set of cells. 
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Topographic, raw transmission and intensity reference data were collected simultaneously, at 
a fixed wavelength, for each SNOM image scan. 
Atomic force microscopy (AFM) imaging of cells 
To further evidence that whole cervical cells had been used to collect the SNOM-IR-FEL 
data, atomic force microscopy (AFM) was performed on the adenocarcinoma stage 1B1 
sample, using a Bruker Innova AFM in contact mode using silicon nitride probes of nominal 
spring constant 0.07 N/m (Supplementary Fig. 10). Topography and deflection (error signal) 
channels were recorded simultaneously. The contact force of the AFM tip on the cells was 
minimised to optimise image quality.  
ATR-FTIR spectroscopy  
Spectra were acquired using a Tensor 27 FTIR spectrometer with a Helios ATR attachment 
(Bruker Optik GmbH). Each spectrum comprised 32 scans at 8 cm-1 wavenumber spacing 
with 2 x interferogram zero-filling. Before the spectra were taken, the crystal was cleaned 
with distilled H2O and inspected by video camera to be free of any contaminants. A 
background spectrum was acquired before the sample slide was mounted and the stage moved 
to bring the cervical cells in contact with the diamond. Spectra were collected from ten 
random sites on the slide. Spectra were converted to absorbance by Bruker OPUS software 
(Bruker Inc., Billerica, MA, USA). 
Pre-processing of SNOM-IR-FEL images  
The raw forward and backward SNOM transmission images were loaded into the freely 
available software Gwyddion 2.40, available at http://gwyddion.net/, and converted into text 
files ready for importing into MATLAB. A second set of raw data files and topographical 
images were converted into jpgs for image enhancement. No other pre-processing was 
performed other than file conversion.  
SNOM-IR-FEL image enhancement   
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The images presented in Figure 6 and Supplementary Figures 1-4 were processed for 
presentation using Gwyddion 2.40 and a median height line correction in the horizontal (fast 
scan) axis, followed by the removal of high frequency noise using a two-dimensional Fourier 
transform. The computational analysis was performed using raw data.   
Computational analysis:  
SNOM-IR-FEL transmission images 
The SNOM-IR-FEL transmission images were processed using MATLAB software 2014a 
and PLS Toolbox version 7.9.3 (Eigenvector Research, Inc., WA, USA). Each SNOM-IR-
FEL data set (transmission images) comprised four matrixes with size of 150 x 150 
corresponding to each biomarker response (Figure. 6). To obtain a spectrum-like signal profile 
from the biomarker response, the biomarker data matrix was converted into a vector by the 
mean calculation of the matrix in the column-mode direction (Equation. 1), where, sj is an 
element of the row-vector s {1 x 150}, corresponding to the spectrum-like signal; m is the size 





Thereafter, the spectrum-like signal was normalized by mean-centring and absolute value. The 
bar charts were made with the area of the spectrum-like signal integrated into an interval of 
spatial distribution according to the cell content position (Figure. 6).  
PCA was performed with the whole spectrum-like signal using only mean-centring and 
absolute value as pre-processing. A summary of the computational steps in processing the 
data is given in Supplementary Fig. 11. PCA is an unsupervised technique commonly used as 
the first step in analysing large, multivariate data sets. Unsupervised techniques require no 
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information from the user but rely instead on an internal criterion to guide learning. In 
unsupervised learning, the system forms clusters (groupings, regions of data space). In general 
terms, PCA reduces the dimensionality of large data sets and using mathematical projection, 
the original data set which may have involved many variables, can often be interpreted in just 
a few variables (the principal components; PCs). This reduced dimensional data set will allow 
the user to spot trends, patterns and outliers in the data, far more easily than would have been 
possible without performing the PCA. When applied to spectra, PCA identifies common 
sources of variance across spectra and collates them into a small number of dimensions. PCA 
is often not enough to segregate out data classes or clusters sufficiently. By applying a 
supervised technique such as LDA to the PCA output, it promotes inter-class variation to be 
identified whilst preventing over-fitting of the data. 
PCA was executed using the average signal of each biomarker (triplicate) for five samples, 
one for each type of cell morphology: normal, low-grade dyskaryosis, high-grade dyskaryosis, 
CIN2, HGCGIN and adenocarcinoma Stage 1B1. Additionally, the area for each biomarker 
for each cell type was determined, as was the percentage area variation from ‘normal’ for each 
biomarker for each cell type.  
ATR-FTIR spectra 
The ATR-FTIR data were analysed using multivariate techniques of PCA for preliminary 
data reduction, and the output was processed using LDA and a variable selection technique 
employing Successive Projections Algorithm (SPA)21, in conjunction with LDA for selecting 
an appropriate subset of wavenumbers for classification purposes. SPA is a variable selection 
technique specifically designed to improve the conditioning of multiple linear regression by 
minimizing collinearity effects in the calibration data set and can result in models with good 
prediction ability22. 
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The classic Kennard–Stone (KS) uniform sampling algorithm23 was adopted to divide the 
available samples into training (70%), validation (15%) and prediction sets (15%) for 
construction and validation of the PCA-LDA and SPA-LDA models. The training set was 
used to obtain model parameters (including variable selection for LDA), and the validation set 
was employed to choose the best number of the PCs for PCA model and to guide the variable 
selection. The optimum number of variables for SPA–LDA was used to select variables 
employing the G function as cost function23.
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Figure legends 
Figure 1. Transmission SNOM-IR-FEL: PC score plots. Scores for 1st and 2nd PCs for the type of 
cells according to each biomarker response: (a) Amide I; (b) Amide II; (c) Lipids; (d) DNA. Dotted 
line indicates 95% confidence limits and shows there were no outliers. CIN2, HGCGIN: Cervical 
intraepithelial neoplasia 2, high-grade cervical glandular intraepithelial neoplasia; PC: Principal 
components; SNOM-IR-FEL: Scanning near-field optical microscopy coupled with an infrared-free 
electron laser.  
Figure 2. Transmission SNOM-IR-FEL: bar chart for each type of cell according to the 
biomarker responses. CIN2, HGCGIN: Cervical intraepithelial neoplasia 2, high-grade cervical 
glandular intraepithelial neoplasia; SNOM-IR-FEL: Scanning near-field optical microscopy coupled 
with an infrared-free electron laser. 
Figure 3. ATR-FTIR Spectroscopy: Discriminant Function (DF) plot for PCA-LDA (6 PC’s). This 
technique promoted a better clustering of the cell types than using PCA alone (Supplementary Fig. 9). 
Dotted regions indicate each class. CIN2, HGCGIN: Cervical intraepithelial neoplasia 2, high-grade 
cervical glandular intraepithelial neoplasia; PCA-LDA: Principal component analysis coupled to linear 
discriminant analysis.  
Figure 4. ATR-FTIR spectroscopy: Discriminant Function (DF) plot for SPA-LDA. Using this 
technique, cells types were clustered more acutely than that observed for PCA-LDA. Dotted regions 
indicate each class. CIN2, HGCGIN: Cervical intraepithelial neoplasia 2, high-grade cervical glandular 
intraepithelial neoplasia; SPA-LDA: Successive projections algorithm in conjunction with linear 
discriminant analysis. 
Figure 5. ATR-FTIR spectroscopy: average raw spectrum and its selected variables (circled) by 
SPA-LDA. SPA-LDA: Successive projections algorithm in conjunction with linear discriminant 
analysis.  
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Figure 6. Transmission IR-SNOM images (400 µm x 400 µm) of the same cell sampled from pre-
invasive lesion (CIN2, HGCGIN) at the different biomarker wavelengths: (a) Amide I - 6.06 µm 
(~1650 cm-1), the horizontal line in (a) is shown in cross section in (b), (c) Amide II - 6.46 µm (~1550 
cm-1), (d) DNA - 8.16 µm (~1225 cm-1) and (E) Lipids - 5.71 µm (1750 cm-1).  The colour scale bar 
arrow indicates increasing biomarker absorption. The shaded region in (b) corresponds to the interval 
selected for area calculation according to the cell content. CIN2, HGCGIN: Cervical intra-epithelial 
neoplasia, high-grade cervical glandular intraepithelial neoplasia.  
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Tables 
Table 1. Important biomarkers (wavenumbers and associated wavelength). a Movasaghi et al, 
200810;  
N.B.: The signal at a particular wavenumber could have contributions from more than one biomarker. 
Amides I and II are linked to the secondary structure of proteins and are indicative of their 
bioavailability.  
Wavenumber (cm-1) and associated biomarker Wavelength (μm) 
~1225 (DNA – asymmetric phosphate)a 8.16  
~1650 (Amide I of proteins predominantly in α helix 
conformation)a 6.06 
~1550 (Amide II of proteins predominantly in β sheet 
conformation)a 6.46 
~1750 (Lipids)a 5.71 
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No of cells 
imaged 16 6 2 5 5 
Age 31 42 Unknown 25 36 
Ethnicity Caucasian Caucasian Unknown Caucasian Caucasian 
Smoker No No Yes Yes No 




ole Nil Unknown Erythromycin Nil 
Recent 
antibiotics 
(within last 2 
weeks) 
No No No Yes No 
Recent pessaries  No No No No No 
Contraception  Nil Copper IUD COCP COCP Condoms 
48 hours since 
last intercourse  Yes Yes Unknown Yes Yes 
Phase of 
menstrual cycle Follicular Follicular Luteal Luteal Unknown 









l Normal Normal Normal  Normal 
Cytology, histology, HPV 
Referral smear Negative Moderate Unknown Severe Severe 
Biopsy NA CIN1 CIN2 Micro-invasive SMILE HGCGIN 
Cone  NA HPV CIN3 CIN2, HGCGIN Adenocarcinoma Stage 1B1 
HPV positive 
test Positive Unknown Positive Positive Positive 
HPV 18  No Unknown No No No 
HPV 16  No Unknown Unknown Yes Yes 
HPV other type  Yes Unknown Yes No No 
Table 2. Patient characteristics. a There was limited data available for the patient diagnosed with High-grade 
dyskaryosis. COCP: Combined oral contraceptive pill: HPV: Human Papillomavirus; CIN2, HGCGIN: Cervical 
intraepithelial neoplasia 2, high-grade cervical glandular intraepithelial neoplasia; IUD: Intrauterine device; POP: 
Progesterone-only pill: NA: Not applicable; SMILE: Stratified Mucinous Intraepithelial Lesion.
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Amide I Amide II Lipids DNA 
Normal -- -- -- -- 
Low-grade dyskaryosis  -73 143 -31 111 
High-grade dyskaryosis -94 40 -78 132 
CIN2, HGCGIN  38 509  93 1272 
Adenocarcinoma Stage 1B1 -66 -46 -47 585 
Table 3. Percentage of area variation (ΔA (%)) from the ‘normal’ cell morphology for each 
biomarker for the type of cell. CIN2, HGCGIN: Cervical intraepithelial neoplasia 2, high-grade 
cervical glandular intraepithelial neoplasia. 
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Table 4. Tentative assignment of biomarkers to wavenumbers. a Movasaghi et al, 20089; N.B.: The 
signal at a particular wavenumber could have contributions from more than one biomarker. 
  
Wavenumber (cm-1) Corresponding wavelength (µm) 
Tentative assignment  
of biomarkersa 
~1022 9.8 Glycogen 
~1157 8.6 C-O Proteins and carbohydrates 
~1184 8.4 Amide III; deoxyribose 
~1234 8.1 Amide III as well as phosphate 
~1331 7.5 vibration of nucleic acids 
~1512 6.6 Polysaccharides; collagen 
~1566 6.4 Amide II 
~1662 6.02 Amide I; ring base 
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Electronic Supplementary Information 
Imaging cervical cytology with scanning near-field optical microscopy (SNOM) coupled 
with an IR-FEL 
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Supplementary Figure 1. SNOM-IR-FEL images of normal cells: (a) topography; transmission images: 
(b) Amide I; (c) Amide II; (d) Lipids; (e) DNA. The colour scale bar arrow in (b) applies to  
(b-e) and indicates increasing biomarker absorption. SNOM-IR-FEL: Scanning near-field optical 
microscopy coupled with an infrared-free electron laser. 
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Supplementary Figure 2. SNOM-IR-FEL images of low-grade dyskaryosis: (a) 
topography; transmission images: (b) Amide I; (c) Amide II; (d) Lipids; (e) DNA. The 
colour scale bar arrow in (b) applies to (b-e) and indicates increasing biomarker 
absorption. SNOM-IR-FEL: Scanning near-field optical microscopy coupled with an 
infrared-free electron laser. 
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Supplementary Figure 3. SNOM-IR-FEL images of high-grade dyskaryosis: (a) topography; 
transmission images: (b) Amide I; (c) Amide II; (d) Lipids; (e) DNA. The colour scale bar arrow 
in (b) applies to (b-e) and indicates increasing biomarker absorption. SNOM-IR-FEL: Scanning 













The SNOM-IR-FEL images and associated topography of the pre-invasive lesion (CIN2, HGCGIN) 
are presented in the main body of the text (see Figure 6). 
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Supplementary Figure 4. SNOM-IR-FEL images of adenocarcinoma Stage 1B1: (a) 
topography; transmission images: (b) Amide I (imaged from different site to topography shown 
here); (c) Amide II; (d) Lipids. (e) Topography of cells from a second area and (f) the 
corresponding SNOM transmission image for the DNA biomarker. The colour scale bar arrow in 
(b) applies to (b-d, f) and indicates increasing biomarker absorption. SNOM-IR-FEL: Scanning 
near-field optical microscopy coupled to an infrared-free electron laser. 
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Supplementary Figure 5. Transmission SNOM-IR-FEL: Hotelling T2 versus Q Residuals 
graphs for the type of cells according to each biomarker response: (a) Amide I; (b) Amide II; (c) 
Lipids; (d) DNA. All 5 samples fell within the 95% confidence limits (blue dotted line), and 
shows there were no outliers. The score for Hotelling T2 ranged from 96.51% to 97.56%; whilst 
the score for Q residuals ranged from 2.44% and 3.49%. CIN2, HGCGIN: Cervical 
intraepithelial neoplasia 2, high-grade cervical glandular intraepithelial neoplasia; SNOM-IR-
FEL: Scanning near-field optical microscopy coupled with an infrared-free electron laser. 
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Supplementary Figure 6. Transmission SNOM-IR-FEL: Validation of the PCA model using Q 
Residuals to measure variation outside the PCA model for each sample according each biomarker 
response: (a) Amide I; (b) Amide II; (c) Lipids; (d) DNA. The optimal score for Q Residuals is 0% 
and here ranged from 2.44% to 3.49%. All 5 samples fell within the 95% confidence limits (blue 
dotted line), shows there were no outliers and that the data fits the model well. CIN2, HGCGIN: 
Cervical intraepithelial neoplasia 2, high-grade cervical glandular intraepithelial neoplasia; SNOM-
IR-FEL: Scanning near-field optical microscopy coupled with an infrared-free electron laser. 
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Supplementary Figure 7. Transmission SNOM-IR-FEL: Validation of the PCA model using 
Hotelling T2 to measure variation within the PCA model for each sample according each biomarker 
response: (a) Amide I; (b) Amide II; (c) Lipids; (d) DNA. The optimal score for Hotelling T2 is 
100% and here ranged from 96.51% to 97.56%. All 5 samples fell within the 95% confidence limits 
(blue dotted line), shows there were no outliers and that the data fits the model well. CIN2, 
HGCGIN: Cervical intraepithelial neoplasia 2, high-grade cervical glandular intraepithelial 
neoplasia; SNOM-IR-FEL: Scanning near-field optical microscopy coupled with an infrared-free 
electron laser. 
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Supplementary Figure 8: ATR-FTIR spectroscopy: Average infrared spectra of cell types. 
 
ATR-FTIR spectroscopy: Attenuated total reflectance, Fourier-transform infrared spectroscopy; CIN2, 
HGCGIN: Cervical intraepithelial neoplasia 2, high-grade cervical glandular intraepithelial neoplasia. 
 Scientific Reports 






Supplementary Figure 9. ATR-FTIR spectroscopy: Scores plot of 1st and 2nd principal 
components at a 95% confidence level. ATR-FTIR spectroscopy: Attenuated total reflectance, 
Fourier-transform infrared spectroscopy; CIN2, HGCGIN: Cervical intraepithelial neoplasia 2, high-
grade cervical glandular intraepithelial neoplasia; Principal components. 
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Supplementary Figure 10. AFM imaging of adenocarcinoma Stage 1B1: (a) Optical image (x10 
magnification) identifying cells for investigation by AFM. (b) AFM topography image of two 
intermediate glandular cells [area 2 in (a)], the lower cell has two nuclei. The cells exhibit a long 
axis of ~75 microns. The cell thickness was measured at ~200 nm, whereas the nuclei protruded  ~1 
micron in height from the substrate. (c) AFM topography and (d) deflection image of a cell 
identified [area 1 in (a)] as having a single enlarged nucleus separated from the rest of the cell by a 
halo. AFM: Atomic force microscopy. 
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4 General Discussion  
4.1 Project One: Tracking the impact of excisional treatment        
Many women undergoing excisional treatments for pre-invasive CIN are of child-
bearing age (Jakobsson and Bruinsma, 2008), yet considerable evidence suggests that 
these types of treatment intervention have an impact on future pregnancy outcomes. 
Cold knife conisation has been shown to be significantly associated with perinatal 
mortality, low birth weight and severe preterm delivery, including Caesarean Section 
(Arbyn et al., 2008; Kyrgiou et al., 2006). LLETZ is associated with a significant 
increased risk of premature rupture of the membranes (Kyrgiou et al., 2006; Sadler et 
al., 2004), and miscarriage in the second trimester (Kyrgiou et al., 2015b), although 
the latter meta-analysis was compromised by the inclusion of non-randomised trials, 
some of which were deemed to be of low quality. Ablative treatments have been 
shown to be associated with fewer adverse sequelae than excisional treatments (Arbyn 
et al, 2008; Bruinsma et al., 2007; Kyrgiou et al., 2006). Therefore, the amount of 
tissue excised appears to have a critical impact on the structure and function of the 
cervix during future pregnancies.  
The findings of our study using biospectroscopy to track the impact of 
excisional treatment for pre-invasive CIN (Project One), showed that treatment 
significantly alters the biochemistry of the cervix, compared with women who 
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have not had local treatment of the cervix. These changes were directly due to 
excision of cervical tissue, rather than the removal of disease.  
It was hoped that different cone depth and/or percentage excisions would be reflected 
in a matched pattern of change in the spectral absorbance and associated biomarkers. 
This pattern of change could then be used to identify women at high risk of adverse 
pregnancy outcomes, who would then benefit from intensive antenatal surveillance 
when pregnant. The original premise of this study was to attempt to identify a clinical 
cut off for excision by comparing one cone depth variable with another, and likewise 
for percentage excision. Where a comparison was found not to be different between a 
higher dimension compared with a lower dimension, the lower dimension was 
proposed to be the optimal clinical cut off (i.e., where excising more tissue conferred 
no additional clinical benefit). Later discussions led to comparisons of absorbance for 
each dimension against that obtained for a healthy cervix population, in addition to the 
multi-comparisons described above. Although the authors concluded that absorbance 
did not seem to correlate to the cone depth or proportion of cervical length 
excised, there are several factors that are likely to have influenced the accuracy 
of the data. Some of these are obvious, such as small sample size; others are 
more confounding and relate to the mechanisms behind underlying patient 
characteristics.  
4.1.1 Sample size and variable selection  
The selection of the amount of cone depth removed as a variable for comparison was 
based upon previously published data that evidenced this dimension correlated to the 
frequency and severity of the adverse events (Arbyn et al., 2008). The selection of 
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percentage of tissue excised as a second variable was based upon the fact that pre-
treatment cervical dimensions vary amongst women (Kyrgiou et al., 2015b), and the 
belief that percentage excision may provide a more accurate cut-off for excision than 
absolute dimensions (Founta et al., 2010). However, our study was not sufficiently 
powered to enable comparisons across all the percentage excision groups, leading to 
the 0-20% group being excluded. Secondly, the number of patients in the remaining 
four groups ranged from 7 to 22 patients. Although the number of patients in the 
groups used in the comparison by cone depth removed was marginally better, with 24, 
24 and 10 patients in the <10 mm, 10-14 mm, and ≥ 15 mm groups, respectively, it 
was acknowledged that the sample sizes were small.  
Scott (2012) stated that ‘even the most rigorously executed study may fail to answer 
its research question if the sample size is too small.’ The overall goal of calculating 
sample size is to estimate a suitable number of subjects that will determine the answer 
of the clinical question(s) of a study. The author of this dissertation was not involved 
in the development of the clinical protocol or the determination of sample size, and it 
is clear that the study was underpowered and unable to address some of the clinical 
questions.   
Furthermore, this study collected additional dimensional data obtained by ultrasound, 
including cone volume removed (cm3), 2D and 3D volume of cervix, and 2D and 3D 
percentage excision. It is feasible that additional analyses using these variables may 
have contributed to defining a more explicit picture with regards to optimal excision 
and off-set some of the limitations of sample size. Potential complementary analyses 
to support the current ones reported here are suggested in Table 8.  
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The limitations of study size should be considered alongside the findings of the post-
hoc analyses of selected underlying patient characteristics (see Section 4.1.2).   
Current analyses Suggested complementary analyses 
Healthy Cervix versus  
Treated by Cone Depth Removed (mm) 
(Individual dimensional groups by 
category) 
Healthy Cervix versus  
Treated by Cone Volume Removed (cm3) 
(Individual dimensional groups by category) 
Not performed Healthy Cervix 2D Volume versus Treated by 2D 
Volume 
(Individual dimensional groups by category) 
Not performed Healthy Cervix 3D Volume versus Treated by 3D 
Volume 
(Individual dimensional groups by category) 
Healthy Cervix versus  
Treated by Percentage Excision 
(Individual dimensional groups by 
category) 
Healthy Cervix versus  
Treated by 2D Percentage Excision 
(Individual dimensional groups by category) 
Healthy Cervix versus  
Treated by 3D Percentage Excision 
(Individual dimensional groups by category) 
Table 8. Additional analyses considered complementary to the current dimensional analyses.  
4.1.2 The mechanisms of underlying patient characteristics  
Several groups have found evidence that an increased risk of pre-term delivery is 
associated with a diagnosis of precancerous changes together with a positive HPV 
status, even in women with an untreated cervix (Huang et al., 2014; Bruninsma et al., 
2007), suggesting that other factors, including patient-specific characteristics and/or 
the HPV infection itself, may contribute to adverse pregnancy outcomes and that 
excisional treatments may exacerbate them.  
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Known risk factors for pre-term birth in women without pre-malignant CIN, include a 
history of induced abortion or miscarriage, previous pre-term birth, infertility 
treatment, current or previous infection with a sexually transmitted disease, being a 
single mother, intimate partner violence, physical workload and those with jobs that 
involves standing for greater than 6 hours a day, alcohol, drug use and cigarette 
smoking (Vicedo-Cabrera et al., 20016; Lumley, 2005; Lumley, 1993). A number of 
these factors, including a current smoking habit, are also associated with an increased 
risk for the development of pre-malignant CIN if present with persistent infection of 
high-risk HPV types (Castellsagué, et al., 2002). It has been suggested that any study 
that does adequately account for these factors in the study design, then any detected 
association with treatment may be due to these other factors rather than the treatment 
itself (Bruinsma et al., 2007).  
Considering the findings of Project One, it was reasoned that a current smoking habit 
may alter the absorbance profile that is distinguishable from non-smokers, and thus 
may have the potential to affect the excisional outcomes. Other patient characteristics 
are known to directly affect the size of the cervix and include age, menstrual phase, 
hormonal status, and parity (IRAC, 2016a).  
Although previous research has shown that Raman spectroscopy can improve the 
classification of LSIL stratified by menopausal and hormonal status from 74% to 97% 
(Kanter et al., 2009), and that ATR-FTIR spectroscopy can discern women infected 
with HPV high-risk types 16 or 18 based upon their age (Kelly et al., 2010), no studies 
have been conducted using ATR-FTIR spectroscopy to determine if the absorbance 
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profile within the ‘fingerprint region’ is different according to a patient’s smoking 
status, menstrual phase, combined oral contraceptive pill (COCP) use, or parity.   
Four post-hoc analyses were performed using the treated group of women used in the 
analysis of cone depth. Patients were classed according to each of the four patient 
characteristics (smoking habit, parity, menstrual phase and COCP use). The analyses 
also included the extraction and comparison of the seven biomarkers used in the main 
analyses. The statistical analyses used have been previously described (see Project 
One); the results are presented in Appendix A.  
4.1.2.1 Current smoking habit 
A post-hoc analysis of treated women detected a significant difference between LD1 
for smokers, compared with non-smokers (Supplementary Figure 1 [A]). No 
significant differences were detected between smokers and non-smokers for 
absorbance associated with the seven biomarkers selected (Supplementary Figure 1 
[B]).  
Fisher’s exact test had previously detected that the number of women in each group 
who were either non-smokers or current smokers was statistically different only for 
Comparison 2 (i.e., treated women with negative cytology and negative HPV versus 
untreated controls with negative cytology and negative HPV); (Supplementary Table 
1). This comparison sought to prove that the difference observed between pre- and 
post-treated patients was due to excisional treatment. The groups were matched by 
cytology and HPV status, but not smoking status. The number of smokers in the 
treated group (segregated by dimensional groups; Supplementary Table 2), ranged 
from 21% to 47%, and all were higher than normal controls (15%).  
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Whilst smoking status is unlikely to affect the physical dimensions of a treated cervix, 
the data suggests that a current smoking habit, although not detected in the seven 
biomarkers selected, alters cervical cell biochemistry. In healthy female smokers, 
nicotine levels are increased by up to 40 times in cervical mucus, with cotinine, 
nicotine’s major metabolite, increased by 4 times, compared with serum levels 
(Sasson et al., 1985). Benzo-alpha-pyrene, an aromatic hydrocarbon found in cigarette 
smoke known to affect DNA repair mechanisms, is listed as a ‘Group 1 carcinogen’ 
by IRAC (2015), and has also been detected in cervical tissue (Melikian et al., 1999). 
Spectra obtained from samples collected from treated women who are current smokers 
are likely to include spectral signatures associated with these compounds. Therefore, 
two confounders are at work here with the potential to affect Comparison 2, and well 
as the dimensional comparisons to normal controls and the individual dimensional 
comparisons to each other: the presence of tobacco-related carcinogens that are likely 
to have an absorbance profile peculiar to them; and the associated effects of these 
carcinogens on cervical cell functionality.  
Analyses to compare smokers and non-smokers within normal controls and in the Pre-
treatment ‘A’ group, would have been preferable to evidence any difference in the 
absence of treatment or pre-invasive CIN. However, there were insufficient numbers 
of patients with a current smoking habit in either group to power the comparisons.  
4.1.2.2 Parity 
Parity, defined as the number of births with >20 weeks gestation (viable and non-
viable [i.e., still born]), has a direct impact on the physical properties of the cervix 
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(IARC, 2016a), changing the physical appearance that can be visualised directly 
(Figure 21).   
 
A     B 
Atlas Human Anatomy (2016).  
Figure 21. The appearance of the external ostium in A: nulliparous women; B: parous women.   
In nulliparous women, the external ostium of the cervix appears as a small external 
opening. In parous women, the cervix is more bulky and the external ostium is 
transformed into a transverse gaping slit.   
A statically significant difference was detected in LD1 between treated nulliparous 
and treated parous women; the result was more significant than that detected for 
smoking status within the same group (Supplementary Figure 2 [A]). However, the 
number of women who were nulliparous in this comparison was >3 times the number 
of women in the parous group; thus significance it likely to be influenced by the 
unequal populations compared. Whilst there were no significant differences detected 
between treated nulliparous and treated parous women for absorbance associated with 
the seven biomarkers (Supplementary Figure 2 [B]), the data suggests parity may 
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permanently alter the function of cervical cells, if not the entire uterus, that is still 
evident even after treatment for pre-invasive CIN.  
Fisher’s exact test found no differences across all three comparisons when comparing 
the number of women in each group who were for parous/nulliparous (Supplementary 
Table 1). However, the number of parous women in the treated group (segregated by 
dimensional groups; Supplementary Table 2), ranged from 17% to 40%, and was 19% 
for normal controls.  Therefore, although the three comparisons were well balanced in 
terms of parous/nulliparous women, the comparison of individual dimensions to each 
other and to normal controls is likely to be affected by the uneven numbers across the 
groups.  
No comparison between nulliparous/parous women within normal controls or the Pre-
treatment ‘A’ group was possible due to an insufficient number of parous women in 
both groups. Therefore, the impact of parity in the absence of pre-invasive CIN or 
treatment, could not be determined. 
4.1.2.3 Menstrual phase  
Menstruation signals the beginning of the follicular phase which culminates in 
ovulation. During this phase, the pituitary gland secretes Follicle Stimulating 
Hormone (FSH) and Luteinizing Hormone (LH), which promotes the maturation of 
around 10-20 follicles in the ovaries. In turn, the maturing follicles secrete oestrogen 
(estradiol) and, as the levels of oestrogen rise over the next 7 days, this causes the 
lining of the uterus to thicken. One follicle becomes dominant and as oestrogen levels 
reach a threshold, the pituitary gland releases a surge of LH, causing the dominant 




FSH: Follicle Stimulating Hormone; LH Luteinizing Hormone.  
Isometrik, 2009 
Figure 22. Phases of the menstrual cycle.  
During the lead up to ovulation, oestrogen causes the ligaments of the uterus to tighten 
which draws the cervix deeper into the vagina. The cervix may appear more centrally 
aligned, feel softer with the external ostium slightly parted. The erupted follicle 
(corpus luteum) begins to produces significant amounts of progesterone, signalling the 
beginning of the luteal phase which lasts for about 14 days. The released ovum is 
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swept into the oviduct, where it will survive for approximately 24 hours. If the ovum 
is not fertilised, the corpus luteum shrinks after 14 days, triggering a sharp decline in 
both oestrogen and progesterone. The cervix returns to its original position, feels 
firmer to the touch with the external ostium closed until the onset of menses. Thus, the 
menstrual phase influences the physical size and location of the cervix. It is unknown 
whether menstrual phase may have affected the determination of cervical dimensions 
by ultrasound as collected in our study.  
Additionally, a recently published study showed that the differential expression of 110 
genes located in endocervix (glandular) tissues is dependent upon the phase of 
menstrual cycle (Yildiz-Arlan et al., 2016); (Table 9).   
 
Associated functions of genes  
expressed in endocervical tissues  
during the follicular phasea 
(Estrogen/pre-ovulation) 
Associated functions of genes  
expressed in endocervical tissues  
during the luteal phasea 
(Progesterone/post-ovulation) 
Extracellular matrix remodelling Chromatin re-modelling 
Cell-matrix interactions Inflammation 
Amino acid and lipid metabolism  Angiogenesis  
Immune regulation Oxidative stress 
 Immune cell regulation 
a Yildiz-Arlan et al., 2016.  
Table 9. Associated function of predominant genes expressed during the menstrual cycle.   
The extracellular matrix of an organ represents the dynamical system that cooperates 
with cells to regulate a range of diverse functions, including proliferation, migration 
and differentiation (Bonnans et al., 2014). Remodelling of the extracellular matrix is 
crucial in many tissues. Dysregulation of the extracellular matrix, including 
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composition, stiffness and structure, are important in several diseases, including 
invasive cancer.  
The follicular phase is predominantly controlled by oestrogen under the influence of 
FSH and LH. Genes expressed by glandular cells during this phase will control re-
modelling of matrix,  cell-matrix interactions, immune function and lipid and amino 
acid metabolism. By contrast, the luteal phase is predominantly controlled by 
progesterone. Genes preferentially expressed during this phase control the remodelling 
of tightly bound DNA (chromatin) to enable gene expression, the development of new 
blood vessels (angiogenesis), together with the management of oxidative stress, 
inflammation and immune cell regulation.  
A statistically significant difference was detected for LD1 between treated patients in 
the luteal phase, compared with treated patients in the follicular phase; this difference 
was the most significant of all four patient characteristics analysed (Supplementary 
Figure 3 [A]). No significant differences were detected between the groups for 
absorbance associated with the seven biomarkers (Supplementary Figure 3 [B]).  
Fisher’s exact test found no significant differences when the comparison groups were 
compared by the number of women in either the luteal or follicular phase 
(Supplementary Table 1). However, the number of women in either the 
luteal/follicular phase in the treated group (segregated by dimensional groups; 
Supplementary Table 2), ranged from 38% to 67%, and was 26% for normal controls.   
Since the number of glandular cells has been found to be significantly lower following 
treatment with LLETZ (Maguire et al., 2008), it is reasonable to assume that the 
number of glandular cells collected during our study at 6 months follow-up after 
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excisional treatment, are likely to contain fewer glandular cells. Although a literature 
search did not find any publication detailing differential gene expression during the 
menstrual phase for squamous cells, it is plausible that cellular function of these cells 
also differs according to each phase.  
Whilst the groups of women in the follicular/luteal phases were reasonably well 
balanced across the three comparisons (Supplementary Table 1); the number of 
women in each phase fluctuated greatly across the treated group (segregated by 
dimensions, Supplementary Table 2), compared to normal controls. Therefore, the 
comparison of dimensional groups to normal controls and to each other, are likely to 
be affected several factors: the effect of circulating hormones on cell activity as 
determined by menstrual phase; the differential gene expression of different cell types 
within each phase; the biochemical behaviour of the tissue and cells as a result of 
different gene expression; and the reduced number of glandular cells collected post 
treatment.  
It was not possible to compare the groups within the normal or Pre-treatment ‘A’ 
group due to insufficient numbers of patients in groups segregated by menstrual phase.   
4.1.2.4 Combined oral contraceptive use   
During the normal menstrual cycle, oestrogen dominates the follicular phase and 
progesterone dominates the luteal phase (Figure 22). The COCP provides an 
exogenous supply of both hormones that together suppress gonadotrophins and inhibit 
the release of FSH, thereby preventing the maturation of follicles in the ovaries and 
ovulation. In doing so, the major effect of progesterone keeps the cycle in an artificial 
‘luteal-like’ phase. It is plausible that genes controlled by progesterone during this 
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phase in glandular cells and potentially squamous cells, would be expressed for 
longer. However, the effect of both hormones combined upon gene expression in 
either cell is currently unknown.   
A statistically significant difference was detected for LD1 between treated women 
who were not taking the COCP, compared with women who used this form of 
contraception (Supplementary Figure 4 [A]). No significant differences were detected 
between the two groups for absorbance associated with the seven biomarkers selected 
(Supplementary Figure 4 [B]).  
The number of women in each group who were non-COCP users or current COCP 
users was found to be statistically different for Comparison 2 (i.e., treated women with 
negative cytology and negative HPV versus untreated controls with negative cytology 
and negative HPV); (Supplementary Table 1); and for Comparison 3. The number of 
current COCP users in the treated group (segregated by dimensional groups; 
Supplementary Table 2), ranged from 40% to 57%, and all were higher than normal 
controls (15%). These findings suggest that COCP use possibly alters differential gene 
expression and related cellular and extra-cellular functions; thus impacting the 
excisional outcomes of our study.   
It was not possible to compare the groups within the normal or Pre-treatment ‘A’ 
group due to insufficient numbers of patients in groups segregated by COCP use.   
4.1.2.5 Other factors: genetics of exfoliated cells and cervical tissue  
The number of genes of exfoliated squamous cervical cells collected from the 
terminally differentiated superficial layers of the cervix has been found to be lower 
than in underlying tissue (Steinau et al., 2005). Of the 25,353 genes of the transcribed 
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human genome, 57% of these genes were found in cervical tissue and 40% were found 
in exfoliated cells, with 7320 genes found in both tissue and exfoliated cells, 
suggesting that exfoliated squamous cells have a more conservative genetic makeup 
than associated tissue. Genes found only in tissue were associated with a range of 
molecular functions, including those of the extracellular matrix. Genes found only in 
exfoliated cells were also associated with a range of functions, including protein 
phosphatase activity.  
Although the healing process following excisional treatments like LLETZ is 
considered to be almost complete around 6 months after treatment (Paraskevaidis et 
al., 2002), cervical regeneration is dependent upon both the percentage of tissue 
remaining immediately after treatment, and the percentage of cone volume removed 
(Papoutsis et al., 2012); less remaining tissue and larger cone removal are associated 
with less regeneration. The effect of treatment on the genetic makeup of cells at the 
superficial layers of the remaining cervix is unknown, as is the effect of treatment 
upon the genetic makeup of deeper tissue and may directly impact on the 
bioavailability of biomarkers. Therefore, the results of our study are complicated 
further by unknown genetic traits of treated tissue.      
4.1.3 Summary 
Although the groups were reasonably well matched in Comparison 1 (same patients 
pre- and post-treatment) for smoking status, parity, menstrual phase and COCP use, 
the groups were not well matched for smoking status and COCP use in Comparison 2. 
This comparison sought to evidence that the difference in absorbance (LD1) was due 
to the excisional treatment. Comparison 3, which compared dimensions against 
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normal controls and with each another, was not well matched for COCP use 
(Supplementary Table 1).  
The findings of the post-hoc analyses suggest there is a complex interplay of 
underlying patient characteristics involving genetics, carcinogens, hormones, and the 
features of regenerated cervical tissue, in addition to other factors that can affect the 
physical aspects of the cervix such as parity. Of note, was that smoking, previous 
parity and COCP use all depressed LD1; the reasons are unknown. In Comparison 2, 
the LD1 of treated patients was lower than normal controls. It is likely that the effects 
of smoking and COCP use in this  group contributed to the result.  
Future studies should aim to investigate the full range of patient characteristics that 
can influence cell biochemistry and function, and contribute to spectral absorbance. 
Comparison groups should be well matched by characteristics.  
A summary of potential factors that may influence the biochemical functions of 




COCP: Combined oral contraceptive pill; IRAC: International Agency for Reach on Cancer.  
Jo’s Cervical Trust, 2016 (modified by D. E. Halliwell) 
Figure 23. Patient characteristics that may affect excisional outcomes determined in Project One. 
4.2 Project Two: The future role of SNOM-IR-FEL imaging in 
cancer studies 
The results of the SNOM-IR-FEL pilot study were promising in terms of tracking the 
changes associated with various degrees of cervical dyskaryosis, although limited by 
the number of patients and individual cells imaged. However, at the time of the 
experimental period (February to May, 2015), the effect of the underlying patient 
characteristics had not been determined.   
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The samples had been collected from one normal patient and four patients with 
increasing grades of dyskaryosis. Although the last four samples were collected prior 
to treatment, it is reasonable to assume that the same patient characteristics 
investigated post-hoc in treated patients, also affect the spectra of untreated patients 
and may, in the presence of HPV infection, be more exaggerated. Two of the five 
patients were current smokers (high-grade dyskaryosis and the mixed pre-invasive 
lesion). Only one patient was parous (low-grade dyskaryosis); two patients were 
sampled in the luteal phase of their cycle (high-grade dyskaryosis and the mixed pre-
invasive lesion), and two patients had been sampled in the follicular phase of their 
cycle; the other was unknown. Finally, two patients were using the COCP (high-grade 
dyskaryosis and the mixed pre-invasive lesion). Although, the small number of 
patients in this study was acceptable for a pilot study, it is clear that the chemical 
images collected are likely to be affected by differences in smoking habit, parity 
history, menstrual phase and COCP use. Other, currently undetermined patient 
characteristics such as vaginal pH and the microbiome of the cervicovagina, are also 
likely to influence the chemistry profiles of different lesions.  
Previous work using SNOM-IR-FEL used in reflection mode, revealed the 
organisation of mitochondria within the mid-piece region of the tail of human sperm 
as well as acrosome and nucleus (Andolfi et al., 2015). However, to an untrained eye 
these individual structures are not obvious. Indeed, the SNOM topography obtained 
during Project Two revealed little in terms of cellular structures and was affected by 





Figure 24. Topography of normal cells: ‘dolphin-nosed’ cells considered to be tip artefacts 
 
Project Two 




Despite the less than ideal topography, the potential of SNOM-IR-FEL is that the IR-
FEL on the ALICE accelerator at Daresbury Laboratory (Warrington, UK) is tuneable 
over the range of 5.5 µm to 8.8 µm (~1818 cm-1 to ~1136 cm-1), which includes a 
number of biologically important biomarkers (Movasaghi et al., 2008). Although no 
formal statistical tests were performed on the data due to the small data set, clear 
differences in each biomarker was evident and appeared dependent on the 
biochemistry of each cell type. However, any future studies using this technology 
should aim to match samples at least by smoking status, parity, menstrual phase and 
COCP use.  
Further studies using the Daresbury facility should aim to address several issues, 
including achieving a higher resolution than that achieved in this pilot study (currently 
~6 µm); the refinement of tips to minimise tip artefacts; and preparation of samples to 
minimise the loss of available cells to image. The latter may be achieved by 
experimenting with manual mounting onto slides rather than using the cytospinner. 
Researchers should aim to image a consistent number of cells per patient and if time 
allows, a higher number of cells per patient, and at the same wavenumbers and 
associated wavelengths documented here to build up a more explicit picture of 
chemical changes within various grades of cervical dyskaryosis.  
All technologies are entitled to their birth right, and SNOM-IR-FEL is no exception. 
The technique, although fraught with early development limitations, is tuneable to 
specific wavelengths, which offers researchers a unique opportunity to investigate 
chemical changes within cells with precision. Whilst only four biomarkers were 
investigated during the pilot study, the range available with the IR-FEL on the ALICE 
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accelerator offers the opportunity to investigate other biomarkers of significance, 
including the N-H bond of thymine (~1272 cm-1), the C=N bond of guanine (~1528 
cm-1), the C=N bond of adenine (~1571 cm-1), and the C=N bond of cytosine (~1602 
cm-1). Investigation of these biomarkers may reveal patterns of change within the 
structure of DNA. The value of Project Two is strategic in that the published paper 
from the 2015 beam time will be used to support a new grant application to fund 
further studies.  
4.3 Future work: meta-analysis  
Despite the limitations of the two projects, the value of Project One lies in its potential 
to contribute to a future meta-analysis. Previous research conducted by Martin’s 
Biophotonics Group has amalgamated spectra obtained from cervical cells collected 
from over 1300 patients (Table 10). 
Number of patients (spectraa) Associated publication  
220 (220) Present study 
350 (322) Gajjar et al., 2014 
67 (67) Purandare et al., 2014 
529 (529) Purandare et al., 2013 
147 (147) Kelly et al., 2010a 
30 (30) Kelly et al., 2010b 
20 (20) Walsh et al., 2007 
Total: 1363 (1268)  
a Ten spectra are typically collected per patient and then an average of these taken.  
Table 10. Number of patients (spectra) collected and stored on the Biophotonics Server.  
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These data provide a rich opportunity to overcome the limitations of sample size, 
investigate a range of patient characteristics, and provide a substantial study 
population where patterns of cellular change can be more accurately matched to 
excisional data. However, the demographic data collected for Project One was 
considerable (63 variables). The other studies listed in Table 10 are thought to have 
more limiting demographic data associated with them, but if the data can be collected 
retrospectively, it would provide a substantial dataset to support addressing key 
clinical questions.   
Suggested approaches for the meta-analysis include:  
• Initially, define patient characteristics within a normal population, including 
the ‘normal’ microbiome diversity of the cervicovagina  
Then determine the changes within the following populations: 
• Women with HPV infection but without any obvious cytological change 
• Women with low-grade dyskaryosis  
• Women with high-grade dyskaryosis  
• Women before and after excisional treatment for pre-invasive CIN 
• Women with invasive cervical carcinomas and adenocarcinomas.  
4.4 Conclusions 
ATR-FTIR biospectroscopy detected changes in cervical cells pre- and post-treatment 
following excisional intervention for pre-invasive CIN. Although it was concluded 
that these changes were directly due to excisional treatment, and the spectra did 
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not seem to correlate to the cone depth or proportion (percentage) of cervical 
length excised, the study findings are hampered by the limitation of sample size 
and the previously undetermined effects of underlying patient characteristics. 
However, the extensive database of cervical cell spectra could support a meta-
analysis involving over 1300 patients that would enable many of these problems to be 
overcome.  
The future of SNOM-IR-FEL lies in the precise investigation of chemical changes in 
cervical cells in different stages of dyskaryosis, with an emphasis on changes within 
the four previously selected biomarkers (DNA, lipids and amide I and amide II bands), 
with potential explorations investigating changes in the four nucleobases of DNA.      
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Appendix A: Supplementary analyses 
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The full statistical methodology has been previously described (see Project One). In 
brief, the treated group used in the aforementioned project (cone depth removed) was 
segregated by smoking status, menstrual phase (luteal or follicular) and parity. These 
four groups were  compared using means, SD and a student’s t test. The same seven 
individual biomarkers at the following wavelengths were also extracted and compared 
using multiple t tests and corrected for using the Holm-Sidak method: ~1030 cm-1 
(glycogen/collagen); ~1072 cm-1 (symmetric phosphate I of DNA); ~1170 cm-1 
(glycomaterials and proteins); ~1223 cm-1 (asymmetric phosphate I of DNA); ~1470 
cm-1 (lipids); ~1550 cm-1 (amide II) and ~1651 cm1 (amide I). The results for smoking 
status, parity, menstrual phase and COCP use are presented in Supplementary Figure 
1, Supplementary Figure 2, Supplementary Figure 3, and Supplementary Figure 4, 
respectively.  
Supplementary Tables 1 and 2 present the patient characteristics (smoking, parity, 
menstrual phase, and COCP use) for each group. Characteristics were tested for 
significance (alpha value = 0.05), using Fisher’s exact test.  
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 Comparison 1: Treated 





Comparison 2 : Normal post-





Comparison 3: Treated by cone 


















































Smoking status, n/N (%)   0.77   0.04*   0.18 
   Non-smoker 23/29 (79) 25/33 (76)  27/39 (69) 19/20 (95)  41/58 (71) 23/27 (85)  
   Current smoker 6/29 (21) 8/33 (24)  12/39 (31) 1/20 (5)  17/58 (29) 4/27 (15)  
Parity, n/N (%)   1.00   0.52   0.51 
   Nulliparous 21/29 (72) 24/33 (73)  32/39 (82) 15/20 (75)  45/58 (78) 22/27 (81)  
   Parous 8/29 (28) 9/33 (27)  7/39 (18) 5/20 (25)  13/58 (22) 5/27 (19)  
Phase of menstrual cycle, 
n/N (%) 
  0.40   0.14   0.08 
   Luteal 15/29 (52) 18/33 (55) 0.60 21/39 (54) 6/20 (30) 0.23 29/58 (50) 7/27 (26) 0.12 
   Follicular 13/29 (45) 11/33 (33)  14/39 (36) 9/20 (45)  23/58 (40) 14/27 (52)  
   Unknown 1/29 (3) 4/33 (12)  4/39 (10) 5/20 (25)  6/58 (10) 6/27 (22)  
Contraceptive use, n/N 
(%) 
         
  COCP 14/29 (48) 17/33 (52) 1.00 20/39 (51) 3/20 (15) 0.01** 28/58 (48) 4/27 (15) 0.004** 
  Other 15/29 (52) 16/33 (48)  19/39 (49) 17/20 (85)  30/58 (52) 23/27 (85)  
COCP: Combined oral contraceptive pill; HPV: Human papillomavirus.  












Percentage Excisionb  
(n=53) 
 
 Category 1:  
<10 mm  
(n=24) 
Category 2:  
10-14 mm  
(n=24) 
Category 3:  
>= 15 mm 
(n=10) 
Category 2:  
11-20% 
(n=9) 
Category 3:  
21-30%  
(n=22) 






Smoking status, n/N (%)         
   Non-smoker 23/27 (85) 19/24 (79) 15/24 (63) 7/10 (70) 7/9 (78) 17/22 (77) 8/15 (53) 5/7 (71) 
   Current smoker 4/27 (15) 5/24 (21) 9/24 (37) 3/10 (30) 2/9 (22) 5/22 (23) 7/15 (47) 2/7 (29) 
Parity, n/N (%)         
   Nulliparous 22/27 (81) 19/24 (79) 20/24 (83) 6/10 (60) 8/9 (89) 18/22 (82) 12/15 (80) 5/7 (71) 
   Parous 5/27 (19) 5/24 (21) 4/24 (17) 4/10 (40) 1/9 (11) 4/22 (18) 3/15 (20) 2/7 (29) 
Phase of menstrual cycle, 
n/N (%) 
        
   Luteal 7/27 (26) 14/24 (58) 9/24 (38) 6/10 (60) 6/9 (67) 12/22 (55) 6/15 (40) 3/7 (43) 
   Follicular 14/27 (52) 8/24 (34) 12/12 (50) 3/10 (30) 3/9 (33) 10/22 (45) 6/15 (40) 3/7 (43) 
   Unknown 6/27 (22) 2/24 (8) 3/24 (12) 1/10 (10) 0/9 (0) 0/22 (0) 3/15 (20) 1/7 (14) 
Contraceptive use, n/N 
(%)         
   COCP 4/27 (15) 12/24 (50) 12/24 (50) 4/10 (40) 5/9 (56) 12/22 (54) 6/15 (40) 4/7 (57) 
   Other  23/27 (85) 12/24 (50) 12/24 (50) 6/10 (60) 3/9 (44) 10/22 (46) 7/15 (60) 3/7 (33) 
a Patients were included in the dimensional analyses if they had had treatment and had follow up data at 6 months after treatment. b There was insufficient patients in 










Supplementary Figure 1. PCA-LDA scores plot of ATR-FTIR spectra with regards to LD1/Absorbance (a.u.) per wavenumber: treated by smoking status.  
The two groups were significantly different along LD1 (Mean/SD: Non-Smoking = 0.14/0.09; Smoking = 0.06/0.12; p=0.01, 95% CI = -0.013 to -0.02). There was no 
significant difference in absorbance associated with each of the seven biomarkers between non-smokers and smokers. ATR-FTIR: Attenuated total reflectance Fourier-




Supplementary Figure 2. PCA-LDA scores plot of ATR-FTIR spectra with regards to LD1/Absorbance (a.u.) per wavenumber: treated by parity.  
The two groups were significantly different along LD1 (Mean/SD: Nulliparous = 0.50/0.08; parous = 0.42/0.08; p=0.002, 95% CI = -0.133 to -0.031). There was no 
significant difference in absorbance associated with each of the seven biomarkers between nulliparous and parous women. ATR-FTIR: Attenuated total reflectance Fourier-




Supplementary Figure 3. PCA-LDA scores plot of ATR-FTIR spectra with regards to LD1/Absorbance (a.u.) per wavenumber: treated by menstrual phase.   
The two groups were significantly different along LD1 (Mean/SD: follicular phase = 0.07/0.07; luteal phase = 0.14/0.07; p=0.0007, 95% CI = -0.11 to -0.03). There was no 
significant difference in absorbance associated with each of the seven biomarkers between women in the luteal phase compared with women in the follicular phase. ATR-
FTIR: Attenuated total reflectance Fourier-transform; CI: Confidence interval; LD1: Linear Discriminant 1; PCA-LDA: Principal Component Analysis-Linear Discriminant 




Supplementary Figure 4. PCA-LDA scores plot of ATR-FTIR spectra with regards to LD1/Absorbance (a.u.) per wavenumber: treated by COCP status.   
The two groups were significantly different along LD1 (Mean/SD: Non-COCP = 0.82/0.03; COCP = 0.78/0.06; p=0.004, 95% CI = -0.07 to -0.02). There was no significant 
difference in absorbance associated with each of the seven biomarkers between non-COCP compared with COCP. ATR-FTIR: Attenuated total reflectance Fourier-transform; 
CI: Confidence interval; COCP: Combined oral contraceptive pill; LD1: Linear Discriminant 1; PCA-LDA: Principal Component Analysis-Linear Discriminant Analysis 
cascade; SD: Standard deviation. * Contraception status was unknown for 5 patients; patients were excluded from analysis.  
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Appendix B: National Research Ethics Service Committee 















Appendix C: Laboratory protocol (preparation of cervical 
LBC samples for ATR-FTIR spectroscopy) 
 105 
 
Protocol for LBC Samples – lab preparation 
Aim: This protocol aims to wash cervical cells collected at colposcopy clinic and 
immediately fixed into an alcohol-based fixative. The washing stage removes the 
alcohol (and therefore any spectral signature associated with it), rehydrates the cells 
and helps remove other cofounding factors, such as blood.  
Safety:  
Wear protective gloves/Howie/safety glasses if cutting.  
Use the clinical bin for waste disposal; decant any collected suspension into the liquid 
waste.   
Materials:  
Bench top centrifuge with a 2000 rpm setting.  
dH2O. 
Low-e slides (cut into 3) for economy. 
Mini petri dishes.  
Non-sterile pipette tips. 
Pipettes.  
Blue roll. 




1. Decide how many samples you wish to process and pre-label micro tubes and 
mini petri dishes with the sample number (label bottom of petri dish as well as top).  
2. If cutting slides, ensure white tip is facing upwards and place a cut segment 
into each  petri dish.   
3. Agitate selected samples to re-distribute the cells.  
4. Decant 500 µl from sample into clean, pre-labelled micro tube. Replace 
original samples into fridge.  
5. Washing stages:  
a. Wash #1: Centrifuge sample at 2000 rpm for 5 minutes to draw a pellet at 
the bottom of the tube.  
b. Wash #2: Decant the ThinPrep from above the pellet using clean tip, taking 
care not to disturb it. Discard tip, replace with clean tip and add 500 µl of clean 
distilled water to tube. Repeat centrifuge step.  
c. Wash #3: repeat step b.  
6. Decant the water from above the pellet and add 100 µl of clean distilled water 
to tube.  
7. Agitate sample to redistribute the cells.  
8. Draw up cells using 100-200 µl setting, ensuring you have the entire sample. 
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9. Discharge sample onto slide in mini petri dish and allow to air dry for 24 
hours. (Optional: leave lid ajar to promote faster drying). Discard micro tube into 
clinical waste.  
10. For repeat samples where the pellet is small and therefore the number of cells 
less, dispense the final 100 µl as two x 50 µl aliquots, allowing a 24-hour drying 
period in between each application, and dispense the second aliquot directly on top of 
the first to promote a uniform spread of cells.  
11. Once air dried, replace lids and collect into small batches and tape together. 
Label and place in a desiccator for a minimum of 24 hours to remove any remaining 
water.  
12. Aim to prepare and collect spectra in within the same time window for each 
batch.  
13. Once spectroscopy has been performed, replace samples back into desiccator.  
Spectroscopy analysis 
Pre-testing: 
Click measure/advanced/Check signal – click save – dot should be in middle.  
14. Humidity test each run should be zero% (click internet 
explorer/diagnostics/check detectors should be zero%. 
15. However, 10% is acceptable. Click on diagnostics and detectors to check 
humidity – above 10% change desiccator (see below). 
16. Close diagnostics down before running tests. 
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17. If prompted run tests but you need to remove unit. 
18. Open video control panel – PW = ‘OPUS.’ 
19. Open video control panel to view diamond. 
20. Clean diamond with distilled water to remove any debris and dry.  
21. Click ‘Advanced measurement,’ then ‘background signal channel.’ Wait for 
the scan to finish.  
22. Load slide – click ‘advanced’ tab and add in details of the sample name.  
23. Change the pathway to the folder where you want to store your spectra. 
24. Click ‘single channel scan’ to view the spectral image and adjust as necessary 
to get the water peak around 0.17-0.2. The amide groups should be clear. The trick is 
consistency. Use the same machine for all samples.  
25. When you are ready to start, click ‘start measurement’ and it will take 32 scans 
containing 235 data points.  
26. The slide needs to be touching the diamond. The water peaks should be peaks 
and not curves. If curves, return to desiccator for further drying.  
27. When the scan has finished, move the slide a little and re-scan. You need to do 
this 10 times but as the count starts from zero, it will run from 0-9.  
28. The area we are interested in is between 900-1800.  
29. If the machine becomes stuck, unload you files first to send them to your 
folder. Switch off the machine and clean, then run background check again. 
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30. To unload files, click the number above image ‘0’, right mouse click, then 
click on last image, the right click to get unload menu, click unload. These images will 
then be sent to your folder.  
31. You are looking to achieve consistency across the images. The density of the 
cells in contact with the diamond influence the resulting image. Better density 
improves the image output.  
Changing the desiccator  
32. Turn off machine at switch. 
33. Use large Allen key to remove hood.  
34. Remove desiccator tube and replace hood without locking.  
35. If using grey pellets, these are reusable. Replace with dried our pellets kept 
warm in oven. Pour old desiccant into pot and replace to over.  
36. Fill tube with fresh desiccator nearly to top, leaving about an inch.  
37. Replace tube in holder and apply bolt with Allen key to hood.  
38. Leave for about 15 minutes to settle. Re-run detectors. If 10% or under, ready 
to use.  
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Appendix D: Laboratory protocol (preparation of cervical 






Lancaster Mini Protocol – SNOM-IR-FEL experiment 
Aim: This protocol aims to prepare cervical cells on a barium fluoride window as a 
single layer of cells with a minimum of debris.  
Safety:  
Wear protective gloves/Howie/safety glasses if cutting.  
Use the clinical bin for waste disposal; decant any collected suspension into the liquid 
waste.   
Materials: 
LBC samples. 
Barium fluoride windows. 
Barium fluoride slide holders (to hold 3 windows per slide). 
Tissue/slide cases.  
Method 
Two slides per sample 
1. Wash the samples as described in Appendix C, but instead of suspending the final 
pellet in 100 µl of distilled water, if the pellet is large, re-suspend it in 1000 µl of 
dH2O. For smaller pellets, re-suspend the pellet into in 500 µl of dH2O.  
2. Transfer the samples securely to the Pathology Department, Preston Hospital along 




3. The pathologist/cytologist will prepare each window and sample for centrifuging tin 
the cytospinner. The samples will be agitated to disperse the cells and then 5/6 drops 
will be added to the cytofunnel. The samples will be spun onto the barium fluoride 
windows using 3000 rpm for 5 minutes.   
Method for mounting onto the SNOM 
Mount duplicate slides at the same time and fix with blue tack.  
Rotate through 1 area per slide (depending on time) collecting the following 
wavelengths: 
• 8.16 um (DNA) 
• 6.06 um (Amide I) 
• 6.46 um (Amide II) 
• 5.71 um (Lipids) 
• Include 1 repeat scan in addition to above per area for quality control/repeatability 
• If time allows, select a 2nd area on one of the slides.  
 113 
 
Appendix E: Poster presented at The International Society 
for Clinical Spectroscopy (CLIRSPEC) 
This poster was presented it at the “CLIRSPEC Summer School” conference in 
Windermere, 7-10th July 2015 as: 
“CERVICAL CANCER: Can attenuated total reflection 
Fourier-transform infrared spectroscopy replace 
conventional cytology?”  
Diane E. Halliwell, Georgios Theophilou, Pierre L. Martin-Hirsch, Maria Kyrgiou, 




I created this poster based on my ongoing studies (at that time). 
 
…………………………………  ………………………………………… 
Diane E. Halliwell    Professor Francis L. Martin   
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